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ABSTRACT
The Effects of Thymic Hormones on the Proliferation 
of Human Myelogenous Leukemia Ceils
by
Melissa Pompilius
Dr. Biyan L. Spangelo, Examination Committee Chair 
Associate Dean of the College of Sciences 
Associate Professor of Chemistry 
University of Nevada, Las Vegas
Thymosin fraction S (TFS), comprised of an array of small molecular weight 
peptides partially purified from the adult bovine thymus gland, contains multiple 
biologically active humoral factors. TF5 influences T cell differentiation, lymphokine 
production and restores immune deficiencies in a variety of animal models in vitro and in 
vivo. Because TF5 generally enhances immune reactivity, we examined the effects of 
TFS on the proliferation of HL-60 human promyelocytic leukemia cells. Direct viable 
dye cell counting, the MTT reaction, and the clonogenic potential of HL-60 cells were 
used to determine cell proliferation. The potency and efficacy of TFS for the inhibition 
HL-60 cell proliferation was similar in all three measures of proliferation. In contrast to 
HL-60 cells, TFS only induced a modest suppression of human melanoma CRL7686 cell 
proliferation. Known qxiptosis inhibitors did not reverse the effect of TFS on HL-60 cell
111
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proliferation indicating that TFS acts through a non-apoptotic mechanism. The results of 
morphological analyses and the TUNEL assay demonstrate that TFS does not induce 
apoptosis in HL-60 cells, suggesting that the mechanism of inhibition involves cytostasis. 
Further purification of TFS by gel filtration chromatography produces a biologically 
active factor of approximately 20 kDa. Since the parent compound is composed of 
peptides less than IS kDa, these results suggest the possible formation of oligomers. 
Electrophoresis of the active factor on polyacrylamide gels indicates that it contains at 
least four components in the S -  IS kDa molecular weight range.
These results demonstrate that an activity in TFS exerts an anti-proliferative effect in 
human myeloid leukemia cells through a cytostatic mechanism; these studies suggest that 
a thymic hormone immune surveillance mechanism may limit the onset of certain types 
of leukemia.
IV
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Thymus mediated immunity is vital for the preservation of immune function. Age 
and disease-related involution of the thymus is accompanied by parallel decreases in the 
levels of thymic hormones in the thymic epithelium and the periphery (Schulof et al., 
1981, Berthiaume et al., 1999). As shown in Fig 1, thymic hormone decline is attended 
by a decrease in immune reactivity and a corresponding increase in the incidence of age 
related diseases (Goldstein et al., 1975). Furthermore, this decline is correlated with an 
increase in cancer incidence (Goldstein et al., 1975; Low et al., 1978). While the role of 
thymic hormones is poorly defined, growing evidence suggests that, together with 
cytokines, they act within the thymus and the periphery to influence T lymphocyte 
differentiation and therefore, immune function. Much of the effort to clarify tfie 
inununological role of thymic hormones has been performed using a protein extract of 
the bovine thymus termed thymosin fraction 5 (TF5). Several component polypeptides of 
TF5 have been isolated and purified, but not all of its observed biological effects can be 
ascribed to these. TF5 exhibits numerous biological activities that generally enltance 
immune reactiviQr (Reviewed in Low et al., 1979; Spangelo et al., 1997). Further, 
previously reported results from our laboratory demonstrated that TF5 is an effective
I
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inhibitor of proliferation in rat neuroendocrine tumor cells (Spangelo et al., 1998, 2000). 
Other studies have shown that TFS inhibits the growth of some cancer cells in vitro, 
including certain murine leukemia cells (Khaw et al., 1973; Schultz et al., 1976; Petro et 
al., 1982) and human acute lymphoblastic T cell leukemia cells (Ho et al., 1983, 1983a). 
TFS has also been shown to normalize the in vitro mixed lymphocyte response (MLR) 
responses of T cells from leukemia patients.
Because TFS generally enhances irrununity and can moderate tumor activity, and 
because cancer is generally accompanied by impaired cellular immunity, we tested 
whether TFS would inhibit the growth of human HL-60 acute myelogenous leukemia 
cells in vitro.
To clarify the relationships between HL-60 cells, cellular immunity, and thymic 
hormones in the context of this study, pertinent aspects of several topics are reviewed 
briefly: the immune system, the biology and chemistry of thymic hormones, leukemia 
and the origin of the HL-60 cell line, and thymic peptides as immunotherapeutic 
adjuvants.
Immune System
The white blood cells of the human immune system arise in the bone marrow and 
circulate in the blood and lymph. In circulation, they function cooperatively to defend the 
body against infection and cancerous body cells. Hemopoietic stem cells in the bone 
marrow originate three principal classes of white blood cells: phagocytes, B-cells, and T- 
cells. Phagocytes leave the bone marrow and become participants in immediate defense 
and activation of the immune response. These cells, including macrophages and their
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
monocyte precursors, engulf pathogens and enigmatically degrade them. Antigen 
presenting cells, APC's, are macrophages that display protein fragments of engulfed cells 
to facilitate immune system recognition of antigens. Some phagocytes become lymph- 
tissue-associated defenders in the liver, spleen, lymph nodes or other tissue. Here, they 
trap cellular debris and foreign particles, removing them from circulation (Raven and 
Johnson, 1992). Others become mobile defenders circulating in the blood and lymph, 
where they phagocytose circulating pathogens that have not yet infected cells. Cytokines 
such as interleukin-3 (IL-3), interferon-y ( IFN-y), tumor necrosis factor a  (TNFa), and 
IL-4 secreted by infected cells and T- cells activate macrophages at local sites of 
infection. Upon activation, macrophages in turn secrete cytokines such as IL-1, IL-6 , 
IFN- y and TNFa, which signal the onset of the immune response (Aspinall, 1997). IFN- 
y promotes the development of monocytes into additional macrophages for defense. 
Secreted IL-1 activates T-cells that have been stimulated by infected cells and prepares 
them to proliferate (Raven and Johnson, 1992). T-cells, upon activation by macrophages, 
initiate two parallel immune responses: the humoral immune response and the cell- 
mediated inunune response.
The humoral response is the long-range antibody defense orchestrated by the B- 
cells. B-cells in the bone marrow develop cell-specific receptors on their surfaces that 
allow them to recognize particular foreign antigens. They are then released into the 
bloodstream and ^ p h  where they differentiate into plasma cells after encountering 
pathogens. This is accompanied by protein antigen uptake and presentation on the B-cell 
surftue in combination with major histocompatibility complex II (MHC II) molecules. 
This complex can then be recognized by antigen specific helper T cell receptors (Raven
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and Johnson, 1992; Aspinall, 1997). Activated helper T cells (Th) and macrophages 
(APC’s) also secrete cytokines that induce B-cells to produce large clones of plasma cells 
(Raven and Johnson, 1992). The plasma cells secrete specific antibody molecules that 
bind antigens and flag the antigen-bearing cells or viruses for destruction.
The cell-mediated immune response involves the destruction of these flagged 
cells and abnormal (i.e. cancerous) host cells. To achieve this, Th cells secrete a variety 
of cytokines such as IL-2, Macrophage Migration Inhibitory Factor (MMIF), IL-1, IL-4, 
and IL-S. IL-2 induces the proliferation of both cytotoxic T cells (Tc) and additional Th 
cells. Activated Tc cells express specific receptors that recognize the antigen- MHC 
molecule complex on antigen presenting {i.e. dendritic) cells and bind them, inducing 
death by lysis. Depending on the cytokine environment, Tc cells can alternatively induce 
apoptosis in antigen-bearing cells (Aspinall, 1997). Macrophage Migration Inhibitory 
Factor retains macrophages at infection sites (Raven and Johnson, 1992). IL-1, IL-4 and 
IL-S participate in B-cell activation (Aspinall, 1997). Th cells also secrete cytokines that 
trigger the development and differentiation of T-cells.
This T cell maturation takes place in the thymus, a primary lymphatic tissue 
located in the upper thorax just above the heart. The function and physiological role of 
the thymus were not known until the 1960’s when studies established that thymectomy or 
impaired thymic development in newborn animals {i.e. dogs, guinea pigs, rodents) and 
hiunans results in decreased lymphocyte numbers in the tissue and blood, as well as 
failure of immunological competence. These studies led to the recognition that primary 
transplant, tumor, microbial, and fungal immunities are under thymic control in mammals 
(Low and Goldstein, 1978).
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The human thymic core is formed by a fusion of two different types of embryonic 
tissue, the 3"* pharyngeal pouch endothelium and the 3"* branchial cleft ectoderm. 
Studies in embryonic mice indicate that the ectodermal layers generate the epithelial cells 
in the thymic cortex, while the endodermal layers produce the epithelia of the medulla 
(Roitt, Brostoff and Male, 1993). In athymic (nude) mouse embryos, this joining of 
ectoderm and endoderm is absent, and the thymus never becomes functional (Kendall, 
1991). Early in the development process, the thymic foundation formed by these two 
layers is divided into two glands by membranes (septa) from the surrounding 
mesenchyme. This division allows the entrance of nerves, blood vessels, and other cells 
into the cortex and medulla. Monocytes enter and differentiate into macrophages that 
populate the cortex and corticomedullary junction, or into interdigitating cells (IDCs) that 
reside in the medulla (Kendall, 1991). All of these cells, along with the thymic epithelial 
cells, display peptides associated with class 1 and class II MHC molecules, proteins 
central to T cell recognition of antigens. The thymus is largest relative to body weight at 
birth, and may gradually be reduced in weight with age, as the bulk of the thymopoietic 
tissue is replaced with fat cells in the process of “thymic involution” (Kendall, 1991). 
The mature thymus provides the microenvironment that controls the development of 
immature T-cells, also called thymocytes, into inununocompetent T-cells.
Prothymocytes from the bone marrow enter the thymus devoid of the molecules 
characteristic of mature T-cells: the CD3- T-cell receptor complex, and the CD4 or CD8  
co-receptors. These double negative (CD4 /CD8  ) cells populate the subcapsular region, 
where they proliferate nq)idly and undergo gene rearrangement to express the cell surface 
receptor and both the CD4 and the CD8  co-receptors. The resulting double- positive cells
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populate the cortex where they undergo positive and negative selection. Approximately 
90% of the double positive cells express receptors that cannot recognize self-MHC 
molecules. These fail positive selection and undergo cell death by apoptosis. The 
remaining positively selected, self-restricted thymocytes occupy the cortex and 
corticomedullary regions, and have increased T-cell receptor expression accompanied by 
loss of expression of either CD4 or CDS. Single-positive cells then undergo negative 
selection, mainly in the corticomedullary junction, to eliminate strongly self- reactive 
thymocytes. Mature T- cells that are self-tolerant and self-restricted leave the thymus via 
the corticomedullary venules or lymphatics. The selection process requires extensive 
interactions between thymic stromal cells (i.e. macrophages, IDCs, and at least six 
subtypes of thymic epithelial cells) and thymocytes involving cytokines (IL’s 1 ,2 ,6 ,7 ,8 , 
IFN- y), and thymic hormones (Bodey, et al., 2000). Two thymic factors that have been 
isolated from a partially purified extract of the bovine thymus (thymosin) have been 
localized in human thymus glands. Cells lining the cortical surface contain both Ta, and 
T^3, whereas only Ta, can be detected in thymic epithelial cells (TEC) of the medulla. 
Further, several peptide components of thymosin can be detected in TECs and 
macrophages in the human thymus cortex and corticomedullary junction (Hirokawa, 
McClure, and Goldstein, 1982; Schuurman et al., 198S). The location of these peptides in 
the thymus, together with experimental data discussed later in this text (Hu, Low and 
Goldstein, 1981) indicates that they participate in specific stages of T cell development. 
The location of thymosin peptides within the cells of the thymus is illustrated in Fig 2. T- 
cell maturation peaks during the first year of life, and declines during thymic involution 
triggered by aging, acute injury, pregnancy, chemotherapy and other forms of stress
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(Berthiaume, et al., 1999; Kendall, 1991). Concurrent with this decline in thymic function 
is a reduction in the secretion of thymic hormones, which have been shown to promote T- 
cell maturation and to modulate peripheral T-cell responses (Goldstein et al., 1975; 
Berthiaume et al., 1999).
Thymosin Fraction S: Purification and 
Characterization
The thymic hormones represent a large heterogeneous group of polypeptides that 
includes the thymosins, thymulin, thymopoietin and a number of less well-characterized 
peptides. The role of these peptides is poorly defined but several lines of evidence 
suggest that together with cytokines they exert significant actions within the thymus and 
in the periphery that influence T lymphocyte differentiation and hence, inunune function 
(Spangelo and Gorospe, 1997). The search for putative thymic hormones began as early 
as 1940, when thymic extracts were shown to stimulate the function and development of 
lymphoid tissue and to moderate the effects of thymectomy in a variety of animal models 
(Low and Goldstein, 1978). Since that time, the biological activities of several thymic 
extracts and their derivatives have been tested in both normal and thymectomized animals 
and in human clinical trials (Oates, Sztein and Goldstein 1989; Spangelo, 1995). The 
results of early attempts to isolate and purify thymic factors that could replace thymus- 
dependent irrununity in normal and thymectomized animals were reported by Goldstein 
and colleagues in the mid- 1960s (Klein, Goldstein and White, 1965, 1966).
Thymosin, a stable, biologically active bovine thymus fraction, was identified in 
1966, and purified to homogeneity in 1972 (Goldstein, Slater and White, 1966; Goldstein
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8et al., 1972). In 1975, Goldstein and colleagues developed a modified purification 
procedure that allowed the preparation of large amounts of thymosin extract, thymosin 
fraction five (TF5) (Hooper et al., 1975). The ability to produce significant quantities of 
the extract facilitated more extensive studies of its biological and chemical properties.
TF5 contains at least twenty heat stable polypeptides with molecular weights in 
the range of 1200-14000. TF5 can be separated on lEF gels into several components. A 
nomenclature system based on the resulting isoelectric patterns has divided TF5 into 
three bands. Peptides with isoelectric points (pi) of less than 5.0 are known as a-peptides 
(acidic). Those with pis of 5.0 to 7.0 are the P-peptides, and those greater than 7.0 are y- 
peptides. Subscript numbers {i.e. TPa, Tp^) identify the peptides from each band in the 
order in which they are isolated (Low et al., 1979). Three peptide components. Ta,, Tp#, 
and MB-35 have been purified and sequenced (Low, et al., 1979; Low and Goldstein, 
1984). Ta, is a highly acidic (pi 4.2), 3108 MW peptide consisting of 28 amino acids 
residues. Tp< has a MW o f4982, a pi of 5.1 and consists of 43 amino acid residues. Both 
of these peptides have been proposed to be thymic hormones. Peptide MB-35 is a basic 
molecule of 35 amino acid residues with a MW of 3756 (Badamchian et al., 1991).
Thymosin is 99% protein with a small amount of carbohydrate and a minute 
amount of nucleotide. Analysis of acid hydrolysates indicates an amino acid composition 
high (approximately 50%) in acidic residues, with very few (~ 3%) aromatic residues, 
and no tiyptophan. Initial studies demonstrated its biological activity in murine systems 
designed to measure lymphocyte function. Thymosin partially restores the responses of 
congenitally athymic mouse lymphocytes to mitogens (Con A, PHA), increases survival 
times and inunune responses to skin allografts (graft versus host reaction, GvH) in
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neonatally thymectomized mice, induces T cell production in adult thymectomized mice 
and enhances the responses of lymphocytes from normal healthy mice to T and B cell 
mitogens. Thus, TFS acts in place of the thymus in thymectomized or athymic animals 
and boosts immune parameters of healthy animals in vitro. Further, thymosin circulates in 
the blood of a variety of mammals. Serum thymosin activity in humans measured by a 
radioinununoassay (RIA) shows lower levels with age, and with the presence of 
immunodeficiency disease, Hodgkin’s disease, or leukemia (CLL) (Hooper et al., 1975).
TF5: Immune System Stimulation 
Subsequent studies have shown that peptide components of TF5 participate in 
diverse immune functions. In animal models in vitro and in vivo, TF5 influences 
thymocyte development and T cell differentiation, induces lymphokine and cytokine 
production, stimulates and restores cellular and humoral immune function, increases 
disease resistance and moderates tumor activity. It has similar effects in human models 
in vitro. TF5 is not universally successful; its effects appear to be dependent on species, 
strain, age, health, and basal immune reactivity of test aiiimals as well as on type of 
disease or tumor investigated and TF5 dose and treatment regimen. Clinically, TF5 
increases resistance to certain diseases, restores immune parameters during disease states 
and moderates the activity of some tumors. Its ability to boost immunity and thwart 
disease and cancer activity make it therapeutically attractive for the treatment of certain 
diseases. Its efficacy in vitro may be an indicator of whether it will have therapeutic 
success for a particular disease.
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Thymosin is extensively involved in thymocyte development and differentiation 
in vitro. It induces the differentiation of mouse thymocytes cultured with allogeneic 
spleen cells in the presence of antigen (Cohen, Hooper and Goldstein, 1975) and also 
induces T cell surface markers (TdT) in murine bone marrow stem cells in vitro 
(Pazmino, Ihle and Goldstein, 1978). Receptors for thymosin are present on rat 
thymocytes, particularly on cells with medium-sized nuclei rich in condensed chromatin 
and on dividing cells (Brelinska and Warchol, 1982). Incubation of rat cortical 
thymocytes with TF5 significantly increases the percentage of rosette forming cells 
(RFC) in this non-RFC rich population. In contrast, the RF percentage of medullary 
thymocytes, which generally do not form rosettes, is not affected by TF5. Spleen fraction 
5 has no effect on either population (Kinoshita, et al., 1986). Additionally, thymosin and 
its component peptides TP] and TP4 impact various thymocyte maturation sequences in 
vivo, such as TdT expression in murine bone marrow cells, and both the early and 
terminal stages of differentiation (Pazmino et al., 1978; Hu et al., 1981). It also induces 
maturation- stimulated expression of mature T cell markers in normal human thymocytes 
(Ho et al., 1983a).
In addition to stimulating differentiation of prothymocytes and thymocytes, pre­
incubation with TF5 stimulates mature T cell activity and lymphokine production by 
murine cells in vitro (Zatz and Goldstein, 1985). Peripheral blood lymphocytes (PBL) 
from thymectomized guinea pigs sensitized with purified protein derivative (PPD) lose 
the capacity to produce MMIF. Normal intact PPD sensitized guinea pig PBLs do not 
experience this suppression. TF5 restores MMIF production in thymectomized animals 
but has no effect on normal intact animals (Thurman et al., 1984). Interleukin 6  (IL-6 ) is
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a pyrogenic cytokine that stimulates pituitary hormone release and participates in T cell 
and B cell differentiation and the induction of IL-2 (T cell growth factor) and IL-2 
receptor (IL-2R) expression. Thymosin in the presence of mitogen causes a synergistic 
increase in lL- 6  production by rat spleen cells in vitro, an activity that is not due to the 
Tai or T^ 4  peptide components of TFS (Attia et al., 1993). Previously published data 
from our laboratoiy suggests that a novel peptide component of TFS enhances rat glial 
cell production of lL- 6  in vitro, and may participate in IL-6 -mediated inflammatory 
responses (Tijerina et al., 1997).
Similar effects have been observed in human cell cultures. In the presence of 
mitogen, TFS enhances lL-2 production by normal human peripheral blood lymphocytes 
(PBL) (Zatz et al., 1984, 1985a; Sztein et al., 1986), an effect that is not due to Tal or 
Tp4 (Zatz et al., 1984, 1985a). In comparison with other well-characterized thymic 
extracts, only one, a closely related porcine preparation exhibited similar activity to TF5 
(Zatz et al., 1984,1985a). The preparation also enhances IL-2R expression. This appears 
to be a direct effect of TF5, since nullification of IL-2 production does not affect the 
outcome (Sztein et al., 1986). TF5 and Tal enhance the mitogen-induced high affinity 
IL-2R expression by human lymphocytes (PBL) in vitro. This effect is coupled with 
increased levels of IL-2 production (Leichtling et al., 1990). Thymosin modulation of the 
IL-2/IL-2R system in vitro involves enhanced IL-1 production by macrophages (Sztein et 
al., 1989; Hu et al., 1989). In combination with aspirin (acetylsalicylic acid), the 
induction of IL-2 synthesis by human PBL is additive, and appears to be mediated by 
monocytes (Zatz et al., 1985b). Studies have shown that aspirin and TF5 also induce IFN- 
Y production in vitro and in vivo in healthy donors. Together, their effects are additive.
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and both require the presence of macrophages to effect the stimulation (Hsia et al., 1989; 
Diezel et al., 1984).
TFS, but not kidney fraction S, stimulates the spontaneous natural killer cell (NK) 
activity of human lymphocytes in vitro. The stimulation of NK activity is additive in 
combination with recombinant IFN-y (Serrate et al., 1987). In addition to increased IL-2 
synthesis, B cell growth factor (BCGF-12kD) production by human PBMC is enhanced 
by TFS, reinforcing the evidence that thymus peptides participate in the regulation of 
humoral (/.e. B cell) immune responses (Kouttab et al., 1988). Furthermore, TFS 
administration in vivo restores the thymus-dependent enhancement of humoral immunity 
by estrogen in adult thymectomized rats, indicating that a hormone product of the thymus 
contained in TFS enhances a specific humoral immune response (Erbach et al., 1991).
TFS: Restoration of Immune Deficiencies
TFS also stimulates and restores cellular and humoral immune deficiencies 
resulting from age, radiation injury, protein deficiency, certain diseases and cancer in 
vitro and in vivo.
Mice can be chemically thymectomized by hydrocortisone treatment, resulting in 
loss of thymocyte and lymphocyte production. Treatment in vivo with mixed interleukins 
{i.e. IL-1, IL-2) prepared from mitogen-stimulated human bufty coat lymphocytes (BC- 
IL; huffy coat interleukins) increases the spleen and thymus weights and cellularity, and 
restores fymphocyte subsets and function in chemically thymectomized aged mice. TFS 
substantially increases the promotion of T lymphocyte development by mixed BC-IL in
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hydrocortisone treated aged mice in vivo, indicating that the two act together to promote 
T lymphocyte development (Hadden et al., 1992).
New Zealand Black (NZB) mice show an age-related loss of T cell functions and 
spontaneously develop an autoimmune and lymphoproliferative disease after 16 weeks of 
age. Abnormal thymocyte proliferation in these animals is prevented by daily intravenous 
injection of TFS (Dauphinee et al., 1974). NZB mice also display an accelerated loss of 
antigen-induced depression of spleen DNA synthesis that can be restored in vivo by 
injection of young NZB thymocytes. TFS treatment also restores this loss for 1-2 weeks 
in vivo. The restoration is repeatable with further TFS treatment (Dauphinee and Talal,
197S).
In an age comparison study of human cells, T cells from normal, healthy older 
(6S-103 years) subjects had lowered immune reactivity (MLR) in vitro as compared to 
young adults (22-41), although both groups had similar peripheral blood T cell counts. 
This decreased reactivity in the aged group was related to an inherent defect in the ability 
of the T cells to respond to mitogen. TFS did not enhance the rosette-forming capacity of 
T cells (TCR) in either group. However, incubation with TFS increased the MLR 
responses of both groups similarly. These results suggest that the decline in lymphocyte 
function with age is not due to a decrease in the population of thymosin-responsive cells 
(Cowan et al., 1981).
Recovery from radiation injury in mice requires thymus-dependent immunity. 
When adult thymectomized, sub-lethally irradiated mice were injected with thymosin, 
percent survival and survival time were both increased significantly over spleen extract 
and saline treated animals, suggesting that thymosin accelerates thymocyte development
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in absence of the thymus (Hardy et al., 1971). The effect of thymosin on the recovery of 
mice from radiation is dependent on the strain and age of mice treated. In three diverse 
strains (CS7Bl/KsJ, CS7B1/6, C3H/HeJ, DBA/1) that were radiation injured, all young 
(<13 wk) animals showed increased thymocyte responses to lL-1. In the DBA/1 strain, 
older animals (>Smo) did not respond to TFS, while age matched C3H/HeJ mice did. 
These results indicate that thymic hormones accelerate the inununological recovery of 
irradiated murine thymocytes in an age and strain dependent maimer (Neta et al., 1985, 
1985a).
Protein deficiency impairs both humoral and cellular immunity. A study of the 
immuno-restorative potential of TF5 demonstrated that it exerts differential effects on T 
cell functions in variably protein- deficient mice. Well-nourished (normal) mice injected 
with phosphate buffered saline (PBS) had significantly increased T cell and B cell 
mitogenic responses. PBS treated mice fed low and zero protein diets had smaller 
increases in induced mitogenesis. Introduction of TF5 treatment in the normal diet group 
gave small increases in mitogenic responsiveness. In the low protein group, TF5 
stimulated mitogenic responsiveness to the levels of the control group. In the zero-protein 
group, TF5 did not have a significant effect on mitogenic response (Watson and Lim, 
1986). In humans, lymphocytes from severely malnourished children had higher RFC 
percentages when incubated in the presence of TF5, indicating the presence of immature 
thymocytes in circulation in these patients and suggesting a potential therapeutic 
application for TF5 in malnutrition (Keusch et al., 1987).
Uraemic animals have increased thymic involution, decreased lymphocyte counts, 
and impaired mitogenic responses. When TF5 was administered to severely uraemic rats.
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both thymus weight and lymphocyte populations were restored, suggesting that TF5 can 
restore suppressed thymic hormone secretion in vivo. (Ikemoto et al., 1992). Pretreatment 
with TF5 also improves the reduced response of thymocytes from severely uraemic rats 
to Con A in vitro (Ikemoto et al., 1990). In contrast, TF5 enhances the in vitro mitogenic 
response of immature lymphocytes from diabetic rats but decreases the mature T cell 
responsiveness (Okimoto et al., 1988).
TF5 restores several depressed immune parameters resulting from disease 
conditions and autoimmune disorders in humans, including lymphokine production, 
mitogenic responsiveness, and T cell differentiation. For example, IL- 2 levels in HIV 
positive pre- AIDS patients were reduced to approximately 20 percent of those in normal 
subjects. lL-2 production increased to 35% of normal levels when mitogen- stimulated 
peripheral blood lymphocytes from pre- AIDS patients were incubated with TF5. Tal had 
no effect (Skotnicki, 1988). In a similar population of patients, TF5 also increased MLR 
responses and stimulated mitogen-induced (PHA, PWM) lL-2 synthesis in peripheral 
blood mononuclear cells (PBMC) from patients with impaired cell mediated immunity. 
These effects are additive when combined with LiCl (Sztein et al., 1987).
In a study of patients with one of several lymphoproliferative disorders, T cells 
from patients with systemic lupus erythematosus (SLE) gave increased immune 
responses {i.e. mitogenic stimulation, T cell colony formation, and erythrocyte rosette 
formation) in the presence of TFS as compared to those from healthy donors. Mitogenic 
responses were increased by TF5 in patients with lymphoproliferative disorders (LPD) 
(Hazama et al., 1978). Additionally, incubation with thymosin enhanced immune
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reactivity and induced CD2 receptor expression of peripheral T cells from severely 
immunodepressed allogeneic marrow transplant patients (Elfenbein et al., 1980).
TFS restores the suppressor activity of lymphocytes from chronic hepatitis 
patients in vitro. Patients with active chronic hepatitis (CAH) had significantly reduced 
suppressor cell activity compared to normal subjects. When lymphocytes from both 
groups were stimulated with mitogen in the presence of TFS, the cells from the CAH 
group had heightened suppressor activity whereas the normal subjects showed no effect 
(Mutchnik et al., 1983). Similarly, pre-incubation with TFS normalized suppressor cell 
activity in peripheral blood lymphocytes from patients with rheumatoid arthritis (Zatz et 
al., 1984a).
TFS also reinstates the loss of immune reactivity due to cancers. Oral 
administration of N-butyl-N- (4-hydroxybutyl) nitrosamine (BBN) induces urinary 
bladder cancer in rats. This results in a gradual decline in lymphocyte rosette forming 
capacity and a progressive reduction in MLR and mitogenic responsiveness of the rat 
thymocytes in vitro that peaks during the hypertrophic stage preceding carcinoma 
incidence. Pretreatment of lymphocytes with TFS restored RFC to near control levels 
(Kimura, et al., 1986), and improved mitogenic activity (Wada et al., 1987). 
Responsiveness was also restored in thymocytes pretreated in vitro with TFS. The 
restorative effects were greater in the hyperplastic stage and early in tumor development 
(Asakawa et al., 1990).
In a study that tested the in vitro effects of thymosin as an inununothenqieutic 
adjunct in humans, cells were taken from patients with disseminated cancers and known, 
limited survival times that had received thymosin injections. Patients in this study
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received no other forms of immunotherapy, and thymosin administration was not given 
on the same days as chemotherapy. In vitro tests measured the blastogénie and MLR 
responses of lymphocytes with and without thymosin. These data were compared to 
responses obtained from lymphocytes taken from normal subjects. In both cases, 
increased T cell response to thymosin was associated with depressed basal levels of T cell 
activity while decreased responses were obtained from subjects with elevated basal 
activity. Thus, thymosin tended to normalize lymphocyte responses in vitro without 
acting as a mitogen or antigen. Clinically, anecdotal observations suggested patients with 
leukemia (ALL, AML, CLL), malignant melanoma and multiple myeloma appeared to 
benefit from thymosin therapy, whereas accelerated disease appeared during thymosin 
treatment in a male patient with choriocarcinoma. No systematic clinical trial was 
conducted, however. Skin test reactivity to antigens was increased in approximately forty 
percent of patients, and gradually declined over a 1-2 month period post treatment. This 
study indicates that thymosin may have potential as an antitumor agent in leukemia 
treatment, that its immunotherapeutic benefit is related to depressed basal lymphocyte 
function, and that in vitro responses may be useful in evaluating candidates for thymosin 
therapy (Schafer et al., 1976).
TFS: Direct Effects on Disease 
And Cancer
In addition to restoring disease and cancer- related immune deficiencies, TFS also 
directly affects disease and tumor progression. Shortly after Goldstein and co lleges 
reported their initial findings that thymosin enhanced T cell ftmctions in vitro (mitogenic 
response, QvH, differentiation), it was tested in the treatment of amyloid disease (e.g.
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Alzheimers) in mice in vivo. This study was logical, since the pathogenesis of amyloid 
disease has been related to immune imbalance, particularly with impairment of T cell 
functions such as poor response to T cell mitogen, impaired GvH reaction, and lowered 
spleen T cell counts. Incidence and severity of amyloidosis induction in low dose (0.5 
mg) thymosin -treated animals was reduced considerably, with a moderate improvement 
of spleen cell response to T cell mitogen. The increase in mitogenic responsiveness was 
higher when TFS was given in high dose (2.5 mg) (Scheinberg, Goldstein and Cathcart,
1976). The effects of TF5 on disease resistance in protein deficient mice compared to 
healthy controls are opposite. Lysteria monocytogenes (LM) is associated with impaired 
T cell immunity. Protein malnourishment impairs LM resistance in mice. TF5 restored 
this resistance, but did not affect NK cell activity. In healthy animals however, TF5 
reduced disease resistance and increased NK activity (Petro, Chien and Watson, 1982). 
Injections of high doses (0.1 mg/day) of TF5 protected mice from streptozotocin-induced 
diabetes and hyperglycemia in vivo. Low dose (0.01 mg/day) TF5 did not have this 
protective effect. Additionally, the effects of thymosin on streptozotocin- induced 
diabetic rats also appear to vary depending on the maturational stage of T cells (Tabata et 
al., 1989). In contrast, TF5 is ineffective in the treatment of some disease conditions. 
For example, none of three different thymosin dose schedules moderated the incidence or 
severity of induced allergic encephalomyelitis in guinea pigs (Woyciechowska, Goldstein 
and Driscoll, 1985).
Thymosin facilitates murine host resistance to oncogenic viruses in vivo. Daily 
thymosin injections (4.0 mg) increased the percent of mice surviving more than twenty 
days after murine sarcoma virus- Maloney (MSV) infection to 69 %, compared to 8
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percent for spleen extract-treated mice and none of control mice (Hardy et al., 1971). 
Splenocytes and thymocytes from Lewis tumor bearing mice enhance tumor growth in 
syngeneic animals. When TFS-treated thymocytes were used in this system, tumor 
growth was significantly decreased (Serrou et al., 1979).
As an anticancer agent, thymosin augmented the rejection of induced Dunning 
leukemia in rats. Effectiveness was dependent upon the time after disease induction that 
therapy started. The mean survival time for control animals was sixteen days, compared 
to greater than 365 days in thymosin treated animals, 60% of which experienced 
complete remission. Injection with normal lymphocytes also increased leukemia 
resistance. This effect was enhanced three fold when the lymphocytes used to treat 
experimental animals were obtained from control animals receiving thymosin injections. 
In contrast, rats receiving rabbit anti-thymocyte serum (ATS), an immunosuppressive 
agent believed to impair thymocyte function, were more susceptible to the disease. Thus, 
the effectiveness of thymosin in augmenting the anti-carcinogenic response may be the 
result of enhanced cellular immunity (Khaw et al., 1973).
Thymosin was also a successful adjunct for increasing tumor resistance of mice in 
vivo, synergistically increasing the effects of specific macrophage reactivity against 
subcutaneous murine MBL-2 or L1210 leukemia injection (Schultz et al., 1976). 
Moderate dietary protein deficiency increases in vivo resistance to LI210 murine 
leukemia cells as measured by lymphocyte mitogenic response in vitro and serum 
corticosterone levels, but not as measured by lymphocyte-mediated cytotoxicity. Protein 
deficiency in combination with TF5 administration in vivo enhanced this resistance as 
measured by all three parameters. TF5 alone also increased tumor resistance, but was not
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correlated to any of these parameters (Petro et al., 1982). In contrast, administration of 
TFS to adult thymectomized mice before and during injection with murine leukemia virus 
(MuLV) increased plasma virus titers, viral replication and the appearance of virus- 
induced membrane antigen, indicating that infection was enhanced (Forger et al., 1976).
Some of the conflicting reports of thymosin’s efficacy as an anti- tumor agent 
may be a function of the tumor type under investigation. The injection of BI6 melanoma 
cells into adult thymectomized irradiated mice results in lower incidence of metastasis 
compared to non-thymectomized control animals. In variants of this tumor, however, 
there is an increase in metastasis following thymectomy and irradiation. When the effects 
of thymosin were compared in both tumor types, it reversed the effects of thymectomy in 
both cases. That is, it increased the metastatic incidence resulting from BI6 melanoma, 
and decreased it in the variant model. Thymosin did not affect metastasis in tumor 
bearing control animals. Thus, TFS can act in lieu of an intact thymus (Naylor et al., 
1983).
TFS is effective as a primary treatment of some chemically induced murine 
tumors in vivo. Pre-incubation of syngeneic bone marrow cells in TFS, followed by 
intravenous administration into tumor bearing mice retarded tumor growth and increased 
survival time. This effect was not achieved with chemically synthesized compounds 
(levamisole, theophylline) that have thymosin-like activity in vitro (Cupissol et al., 1982). 
In the case of BBN induced tumor formation however, 60 pg of TFS administered 
biweekly did not rescue male NON/shi mice from urinary tract carcinomas or metastasis 
of renal pelvic carcinomas (Murai et al., 199S). In contrast, TFS is an effective adjuvant
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combined with S’-deoxy-5-fluorouridine (S’-dFUrd), enhancing its anti-tumor activity in 
mouse bladder cancer cells up to four fold (Ikemoto et al., 1999).
Because TFS stimulates the hypothalamic-pituitary-adrenal (HPA) axis, our 
group also examined its effects on rat neuroendocrine MMQ pituitary adenoma and C6 
glioma tumor cells in vitro. TFS significantly reduces both the proliferative capacity and 
viability of both cell types. Morphological analyses indicate that apoptosis is the anti­
proliferative mechanism. The effect on MMQ cells is partially reversed by MMC  ^cell 
conditioned medium, indicating that these cells secrete an autocrine growth factor that 
opposes the actions of thymic hormones. None of the previously purified thymosin 
peptides (i.e. Ta,, TP4, MB-3S and MB-40) have any effect, so the observed inhibition 
may be due to a novel peptide component of TFS (Spangelo et al., 1998). These results 
suggest that a thymic hormone contained in TFS mediates neuroendocrine tumor 
formation and immune functions in vitro and may have therapeutic value in both 
capacities (Spangelo et al., 2000).
TFS was tested in vitro as a differentiation agent for human leukemic T cells 
(MOLT-3). Incubation with TFS markedly reduces the percentage of cells bearing surface 
markers of immature thymocytes (NAI/34) but does not affect expression of post-thymic 
T cell markers. Thus, TFS induces signs of differentiation in human leukemic T cells in 
vitro (Ho et al., 1983). TFS exerts similar effects in the human thymus-dependent 
leukemia (Thy-ALL) cell lines RPMI-8402 and JMl (Ho et al., 1983a).
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TFS; Clinical Studies 
Clinically, TFS has been used to replace thymus function in the treatment of 
human thymic disorders (i.e. Di George or Nezelof thymic hypoplasia, SCID, primary 
immunodeficiency), especially in cases of primary immunodeficiency, where thymus 
transplantation is problematic. It has also been employed extensively as an adjunct for 
enhancing inununity in “combined modality” studies, particularly in cases where the 
primary treatment regimen depletes or impairs the patients’ immune system (as in 
chemotherapy). In some cases, however, TFS has been a primary treatment, especially in 
autoinunune diseases, or for diseases for which no cure exists or other drugs have been 
ineffective (i.e. hepatitis).
in children with primary immunodeficiency, thymosin treatment increased 
cellular immune parameters both in vitro and in vivo. Weekly thymosin injections 
increased total lymphocytes and percentage of T cells in circulation, and improved 
reactivity to skin tests. In vitro, lymphocytes from treated patients formed more T cell 
rosettes, some responded better to mitogen stimulation and the MLR assay and some 
showed increased immunoglobulin and specific antibody synthesis. Thymosin caused 
partial reconstitution of cellular inununity in patients with thymic hypoplasia who have 
an existing population of thymocyte precursors, and induced an in vitro increase of T cell 
rosette formation by lymphocytes from patients with DiGeorge syndrome. Iti contrast, it 
had no effect in vitro or in vivo on the parameters for patients with SCID, severe 
combined immunodeficiency disease (Wara and Amman, 1976).
The immunorestorative potential of thymosin was tested clinically in an attempt 
to shorten the extended periods needed for marrow graft patients to recover
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immunologically. Despite its success in restoring cellular immunity to lymphocytes from 
marrow transplant patients in vitro, TF5 did not significantly alter immune or disease 
stabilization parameters for human marrow graft recipients (Witherspoon et al., 1983).
TFS is an effective immunorestorative adjunct in the treatment of some patients 
with advanced refractory cancer. In one clinical trial, a single treatment of thymosin 
resulted in significant improvement in several immunoassays designed to measure 
humoral and cell-mediated immune responses (i.e.. E-rosette, MLR). Although no 
decrease in tumor volumes was observed, two patients (14%), one with lung cancer and 
one with thymoma, had disease stabilization for up to six months. No significant 
toxicities, side effects, or complications resulted from thymosin therapy. Improvement in 
immune assays decreased by 48-72 hours, indicating that repeated thymosin 
administration is necessaiy to maintain benefits (Dillman et al., 1983). In contrast, 
sustained TFS administration (120mg/mL biweekly) to patients with advanced colorectal 
cancer that had failed to respond to standard therapies, or patients with hypernephroma 
who had previously failed Tai therapy, elicited no response in similar assays. 
Additionally, no antitumor effects were observed in this trial (Dillman et al., 1987). 
Similarly, administration of TFS (60 mg/m* s.c. twice weekly) to small cell lung cancer 
patients undergoing induction chemotherapy and radiation therapy, including 
prophylactic cranial irradiation, did not alter response rate, response duration, survival 
rates, immune function, or lymphocyte counts (Scher et al., 1988).
Male homosexuals serum-positive for HTLV-lII who entered thertqry with 
abnormal T cell balances and received 60mg of subcutaneous TFS daily for ten weeks 
exhibited improvements in T- lymphocyte immune (MLR) reactivity and transient
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normalization of mitogen-induced IL-2 production. TFS did not alter serum antibody 
titers, and other dose regimens (30, 120 mg) were ineffective. The responses could not be 
sustained when TFS was administered only twice weekly. At a median 20-month follow 
up, none of the patients (6/14) whose MLR improved in response to TFS had progressed 
to AIDS. These results indicate that TFS has therapeutic value for the treatment of 
immune deficiencies in serum-positive HTLV-111 patients in appropriate doses and in 
combination with antiviral drugs (Schulof, et al., 1986).
Several autoimmune disorders possibly related to abnormal T suppressor 
functions responded well to TFS treatment in initial clinical studies. Four patients with 
systemic lupus erythematosus, and one with rheumatoid arthritis and Sjogren’s syndrome 
were given thymosin injections for 2 to 3S months. All patients had higher levels of T 
lymphocytes in circulation after treatment. Pretreatment assays were positive for 
cytotoxicity for all patients, and declined to zero during the course of therapy. Of four 
patients exhibiting clinical improvement, one had disease stabilization (Lavastida et al., 
1981).
Preliminary clinical results indicate that thymosin is effective as a primary 
treatment for chronic hepatitis B. Thymosin treated patients were compared to patients 
receiving placebo, and both groups were compared to healthy volunteers. Six of seven 
thymosin-treated patients responded to therapy. One of the five placebo-treated patients 
experienced complete remission of disease, while the other four showed no response. In 
thymosin patients, serum HBV DNA disappeared and serum ALT levels were 
significantly lower than placebo patients. The thymosin group was negative for serum 
HBV DNA and had normal ALT levels at two years post treatment Thymosin also
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reversed the decrease in peripheral blood lymphocyte, CD4 and CD3 counts caused by 
the disease, and these patients had elevated levels of IFN-y synthesis by peripheral blood 
mononuclear cells (PBMC) as compared to the placebo group and to healthy volunteers. 
Thymosin therapy was also associated with decreased liver inflammation and tissue 
damage, and cessation of viral protein production (HbsAg) and HBV DNA replication. 
Since the thymosins are not known to have antiviral properties in vivo, these clinical 
results may be due to thymic peptide modulation of cellular and humoral immune 
responses (Mutchnik et al., 1991).
Patients undergoing intensive chemotherapy to induce remission of small-cell 
lung cancer did not exhibit higher complete response rates upon the addition of thymosin 
therapy (60 mg/m  ^biweekly for six weeks). However, among the complete responders, 
those who received thymosin had prolonged disease remission and subsequently, 
signiflcantly prolonged survival times (Cohen et al., 1979).
In a clinical trial evaluating the efficacy of TF5 as a primary therapy in advanced 
renal cancer, thymosin treatment of patients who had previous nephrectomy resulted in 
partial regression in 15%, and disease stabilization in 10% of patients. All patients who 
responded to therapy presented with lung métastasés prior to treatment. One patient had a 
50% reduction in diameter of a lung lesion, accompanied by complete clearing of a small 
pleural effusion, after four weeks of high dose (120mg/m2) thymosin administration. In 
this trial TF5 was as effective as chemotherapy in the treatment of advanced renal cancer, 
without the detrimental side effects. These results also suggest that thymosin may be 
effective in the therapy of lung cancer patients (Schulof et al., 1984).
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Thus, TFS and its component peptides participate extensively in immune 
functions, and can improve host defense by stimulating both cellular and humoral 
immunity. Additionally, they can directly inhibit disease and tumor progression. Their 
effects vary depending on the experimental model system and on the type of disease or 
cancer involved. Their effectiveness for a particular function in vitro may be an indicator 
of therapeutic usefulness.
Principle Hypothesis of This Study 
Because TFS is a potent immune enhancing agent that also exerts anti-cancer 
effects, and because the leukemias are cancers that induce severe immune deficiency, we 
hypothesized that TFS would act directly on human leukemia cells to inhibit their 
proliferation. We conducted experiments to test the specific hypotheses that (1) thymic 
peptides inhibit the proliferation of human HL-60 myeloid leukemia cells, (2) this 
inhibition is due to a putative peptide component of TFS, and (3) the mechanism of 
inhibition is apoptosis.
Leukemia and the Origins of the HL-60 Cell line 
The leukemias are cancers that result from the unregulated growth and abnormal 
differentiation of hematopoietic cells and their precursors (stem cells) in the bone 
marrow. The leukemic cells proliferate more and survive longer than normal cells, 
gradually building up in the bone marrow and inhibiting the production of functional 
blood cells. Eventually, aberrant nonfunctional leukocytes spill into the bloodstream and 
ultimately invade other organs and tissues, thwarting normal function. Impaired
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hematopoiesis leads to deficiencies of red blood cells (anemia), platelets 
(thrombocytopenia) and phagocytes (neutropenia, monocytopenia), and disrupts the 
ability to mount a competent immune response.
There are four major classifications of leukemia; lymphocytic leukemias involve 
abnormal development of lymphocytes, while myelogenous (granulocytic) leukemias 
affect cells of the myelocytic lineage. Both of these may be acute or chronic. Acute 
leukemias progress very rapidly; chronic disease progresses more slowly then converts to 
rapid progression or “blast crisis” in the terminal stage.
Acute myelogenous leukemia (AML), also known as acute non-lymphocytic 
leukemia (ANLL) or acute granulocytic leukemia (AGL), results from neoplastic 
transformation of a hematopoietic stem cell in the bone marrow. The cause of 
transformation is generally not known, but several risk factors have been identified. 
These include advancing age (-50% of new cases occur after age 65), impaired immune 
function, exposure to industrial chemicals (i.e. benzene), or exposure to irradiation. 
Paradoxically, chemotherapy, the primary treatment for AML, is also a major risk factor 
for the disease. In fact, AML commonly occurs as a secondary malignancy in patients 
previously treated for cancer (Belcher, 1993; McAllister, Horowitz and Gilden, 1993).
Chemotherapy also contributes to another risk factor for leukemia, impaired 
immune function. It is unclear whether immunodeficiency allows leukemia to develop or 
whether the neoplasm and the immune defect arise from the same genetic injury. Several 
congenital immunodeficiencies however, are associated with increased AML incidence 
(i.e. SCID, neutropenia, Fanconi’s anemia), and the course of AML itself results in severe 
immime defects (i.e. neutropenia, anemia, thrombocytopenia). Without competent
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immune defense, patients are increasingly susceptible to infections (Wiemik et al., 1991; 
Belcher, 1993; McAllister, Horowitz and Gilden, 1993). Impaired immunity is also 
associated with poor prognosis, especially if T cell dependent immunity is affected, as 
exemplified in the case of Hodgkin’s disease. Hodgkin’s disease is a neoplasm affecting 
the lymph nodes, spleen and liver. Otherwise normal patients with Hodgkin’s disease 
have a 66% higher 5-year survival rate then patients with deficiencies involving cell- 
mediated immunity (Wiemik et al., 1991). Because of these factors, there is an emphasis 
on restoring and maintaining inunime functions during AML therapy.
The HL-60 human acute myelogenous leukemia cell line was established from the 
peripheral blood of a patient with AML (Collins, Gallo and Gallagher, 1977). It was 
originally classified as derived from acute promyelocytic leukemia APL FAB- M3, a sub- 
type of the myelogenous leukemias, although the cells were noted to lack several features 
characteristic in APL cells (Collins et al., 1977; Gallagher et al., 1979). It was later 
reported that HL-60 morphology is more accurately classified as AML FAB- M2, an 
acute myeloblastic leukemia with some markers of maturation (Dalton et al., 1988).
This cell line is susceptible to HIV-1 and HTLV-1 viruses. The cells form 
colonies in agar and produce myeloid tumors in nude mice. HL-60 cells are commonly 
used for pharmacodynamics, induction of differentiation studies and antitumor testing 
(Gallagher et al., 1979; Koefiler and Golde, 1980).
Since TF5 generally restores immune deficiencies and inhibits the activity of 
some tumor cells, we tested its effects on human myelogenous leukemia cells.
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CHAPTER 2
MATERIALS AND METHODS 
Chemicals and Reagents 
MTT (3-(4,S-dimethylthiazol-2-yl)-2,5-diphenyl tétrazolium bromide, z-Val-Ala- 
Asp-CHzF (zVAD-fmk), etoposide (VP-16), sphingomyelinase, horse heart cytochrome 
c, trypsin, bradykinin, aprotinin, sephadex G-SO gel filtration beads, reagent grade 
isopropanol, methanol, glacial acetic acid, hydrochloric acid, dibasic sodium phosphate, 
ammonium sulphate, P-mercaptoethanol, Folins reagent and agar were purchased from 
Sigma Chemical Company (St. Louis, MO). Dr. Ronald Gary, University of Nevada Las 
Vegas (Las Vegas, NV) kindly provided DNP-Asp Blue Dextran and Coomassie blue 
stain solution. Penicillin G-streptomycin sulfate antibiotic mixture, streptomycin sulfate, 
RPMl 1640, L- Glutamine, MEM sodium pyruvate solution, MEM non-essential amino 
acids solution, and trypan blue stain were purchased from Gibco BRL (Grand Island, 
NY). Heat-inactivated Fetal Clone I serum was purchased from HyClone, USA (Logan, 
UT). Dr. Mahnaz Badamchian, George Washington University (Washington, DC) 
generously provided thymosin fraction 5 (TFS) and thymus acetone powder (TAP). Dr. 
W. David Jarvis, University of Texas at Houston (Houston, TX) kindly provided the HL- 
60 cell line. The CRL7686 cell line was obtained from the American Type Tissue Culture
29
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Collection (Rockville, MD). Novex™ Tris-glycine 4-20% SDS (sodium dodecyl sulfate) 
and NuPAGE™ Bis-tris 12% pre-cast electrophoresis gels, Novex^ precast vertical lEF 
gels. Mark 12™ electrophoresis protein standard mixture, tris-glycine SDS running 
buffer, tris-glycine SDS sample buffer, NuPage MES (2-(N-morpholino) ethane sulfonic 
acid) SDS running buffer, lEF anode buffer, lEF cathode buffer pH 3-10 and pH 3-7, lEF 
sample buffers pH 3-10 and pH 3-7, and colloidal blue staining kit were purchased from 
Invitrogen Corporation (Carlsbad, CA).
HL-60 Cell Culture
The HL-60 cell line was maintained in continuous culture in a humidified 
atmosphere of S% C02-95% air at 37"C in phenol-free RPMI-1640 supplemented with 
10% heat-inactivated fetal bovine serum, sodium pyruvate, nonessential amino acids and 
antibiotics. Cells were sub-cultured every 3-4 days. Cells were removed from tissue 
culture flasks, rinsed three times with serum- free RPMI (sfRPMI), counted by 
hemacytometer, and either placed in continuous culture (1.0 xl0‘ cells per 25 cm* flask) 
or used in cell culture assays.
Viable Dye Exclusion Assay 
Initial experiments consisted of three groups of cells: one was pre-incubated in the 
presence of TFS for 24 h and then rinsed and assayed, a second was exposed only to 
vehicle (RPMI 1640, supplemented), and a third was assayed in the continuous presence 
of TFS. All groups were cultured at an initial plating density of 1.0 xl0‘ cells/flask in 25 
cm  ^tissue culture flasks and aliquots were removed and counted by hemacytometer each
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day for four days using the viable dye (trypan blue) exclusion assay. Cells were also 
cultured in 12-well culture plates (240 x 10^  cells/3ml/well; Costar, Fisher Scientific, 
Santa Clara, CA) and treated with vehicle or TFS for 24-96 h for the determination of cell 
viability and proliferation using the viable dye exclusion assay. For the TFS metabolism 
assay, cells were cultured in 2S cm  ^ tissue culture flasks (1.0 x 10^  cells/flask; Greiner 
Labortechnik, ISC Bioexpress, Kaysville, UT) in the presence of either TFS, HL-60 
conditioned medium, HL-60-conditioned TFS or vehicle, and aliquots were removed and 
counted by hemacytometer each day for four days
For the MTT assays, HL-60 cells were incubated in 96-well plates for 72 h (20 x 
10^  cells/0.2 ml/well; Greiner) in the presence of either TFS, fractions of TFS, other 
thymus preparations, or vehicle for the determination of cell viability and proliferation. 
In addition, differing numbers of cells (S-30 xlO  ^ cells/well) cultured in 96-well tissue 
culture plates were exposed to TFS for 96 h. After incubation, 20pl of Smg/mL MTT was 
added to each well. After a 4 h incubation period, ISOpl was removed from each well, 
and replaced with an equal volume of 0.04 M HCl/isopropanol. After overnight 
incubation in darkness, the dissolved MTT crystals were quantitated. Optical densities 
were obtained using a test wavelength of S70 nm and a reference wavelength of 630 nm 
(Dynatech MRS000 microelisa spectrophotometer, Chantilly, VA).
Clonogenic Assay
Cell proliferation was also evaluated using a cloning assay. HL-60 cells were 
removed from continuous culture, rinsed three times with sfRPMI and counted ly  
hemacytometer. Various cell numbers (SO-1000 cells/well) were dispersed into 12-well
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plates in a single-layer soft agar system containing RPMI, 20% heat- inactivated fetal 
bovine serum, and 0.3% agar. The plates were incubated at 37°C in 5% C02-9S% air. 
The resulting colonies (>S0 cells) were counted 14 days after plating. In TFS 
pretreatment experiments, cells were removed from continuous culture, rinsed with 
sfRPMI and 1.0 x 10^  cells/lOmL were incubated in culture flasks either in vehicle, or in 
100 - 800 pg/mL TFS for 24 h. They were then rinsed, counted and plated in the agar 
system for enumeration of colony formation after 14 days of incubation. Using the same 
protocol, cells were also incubated for 24h with vehicle, 400 and 800 pg/mL TFS, or 40 
and 80 pg/mL of biologically active RP-HPLC fractions of TFS and plated in the agar 
system. In time-course experiments, 1.0 x 10^  cells/lOmL were incubated in culture 
flasks either in vehicle, or in 400 and 800 pg/mL TFS for 3-24 h. The end points of 
incubation were coordinated so that all cells were removed firom culture or treatment, 
rinsed and plated in the agar system at the same time. To study the effects of apoptosis 
inhibitors, cells were removed from culture as before, and one group was pretreated for 
30 min with the apoptosis inhibitor ZVAD-fmk (dissolved in DMSO), and then incubated 
in the presence of 800mg/mL of TFS. Other groups were incubated with vehicle, DMSO 
(as a control for the ZVAD-fink carrier) or 800 pg/mL TFS. All groups were plated in the 
agar system at the same time. In similar experiments, cells were pre-incubated with 
ZVAD-fink for 30 min and then incubated with sphingomyelinase (Smase), or etoposide 
or 800pg/mL TFS, or cells were incubated with 800pg/mL TFS, DMSO, or vehicle for 24 
h, and then plated in the agar system. As before, incubation times were coordinated so 
that cells were rinsed and plated at the same time.
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Partial Purification of TF5 
TFS was prepared from freshly frozen calf thymus as described by Hooper et al 
(197S). Preparative reverse-phase high performance liquid chromatography (rpHPLC) of 
TFS was performed as described as described by Badamchian, et al (1990, 1991). TFS 
(I S g) was applied to a 5-prep HPLC system equipped with a model 481 variable 
wavelength detector with a semi-preparative flow cell (280 nm) and a 300 x SO mm d-pak
300 A ISpm C|8 column (Waters Chromatography Division of Millipore Corp., Milford,
MA). Eluent A was 0.02 M ammonium acetate (pH 6.8) and eluent B was acetonitrile. A 
60-min linear gradient from 0-80 % B was run at a flow rate of 80mL/min. TFS was 
dissolved in the initial solvent A, applied to the column through a port in the solvent 
delivery system, and one- minute fractions were collected for sixty minutes. Actual 
protein concentrations were determined using the Lowry assay (Lowry et al., 19S1). 
Aliquots from each of the 60 fractions (S-lSpl/well) were added to cultured tumor cells. 
The cells were incubated for 4 days, and the extent of proliferation was determined using 
the MTT assay.
Size-Exclusion HPLC Analysis of TFS 
TFS was further separated by size-exclusion HPLC. 20 or SOpL of TFS dissolved 
in lOmM dibasic sodium phosphate buffer was injected onto an in-line colurrm system 
composed of a Macrosphere GPC lOOA 7p column 2S0 mm x 4.6 nun (i d.) followed by 
a Macrosphere GPC 60A 7p colurrm of the same dimensions (Alltech Associates, 
Deerfield, IL), with a 10 mM dibasic sodium phosphate running buffer. Detection was 
obtained at 220nm (Spectroflow 7S7 absorbance detector, Kratos, Ramsey, NJ). The
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resulting protein peaks were analyzed by PeakSimple Peakll Chromatography Data 
System software (SRI Instruments, Torrance CA.). The fractions collected were 
lyophilized under vacuum in centrifugal desiccation unit (Savant Instruments, Inc., 
Holbrook, NY), and re-suspended in sterile ultrapure water for further analysis.
Gel filtration Chromatography 
Purification of TFS components was achieved by gel filtration chromatography. A 
Kontes (Fisher Scientific, Santa Clara, CA) 1.5 x 30 cm (50 mL) filtration column was 
packed with Sephadex G-50 beads in lOmM sodium phosphate buffer adjusted to pH 7.0. 
The flow rate was maintained at 1.40 mL/min. The outer and inner column volumes were 
defined as the elution volumes of blue dextran (5 mg/mL) and DNP-Asp (0.5 mg/mL) 
respectively. Bradykinin MW -1050), cytochrome c (MW -12,000), and trypsin (MW 
-24,000) were used as protein standards. From their elution volumes, the elution 
coefficient, K was determined, using the following equation:
K = (Ve-Vo)/(V,-Vo)
Where V, is the elution volume of a solute, Vo is the volume outside of the beads in the 
column, and V, is the total volume occupied by the gel bed.
A plot of the log of the molecular weight versus the K for the standard proteins 
was used to estimate the molecular weight of the TF5 Auctions. TF5 dissolved in lOmM 
sodium phosphate was applied to the column and the resulting fractions were collected 
and stored at -70°C. They were later lyophilized under vacuum in centrifugal desiccation 
unit (Speedvac SC 100, Savant Instruments, Inc., Holbrook, NY), and re-suspended in 
sterile ultrapure water for further analysis.
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Electrophoresis
SDS PAGE electrophoresis (Laemmli) and isoelectric focusing were carried out 
in a mini-vertical electrophoresis system (Novex Xcell Surelock Mini-Cell, Invitrogen) 
on pre-cast 10- well gels in accordance with the manufacturers protocols (Invitrogen- 
Novex™). Initial SDS PAGE gels were 4-20% tris-glycine polyacrylamide gels buffered 
to pH 8.7 with a tris-glycine-SDS (2.9%, 14.4%, 1%) running buffer (upper and lower 
chambers) pH adjusted to 8.3. The sample buffer was composed of 0.5 M Tris-HCl, 20% 
glycerol, 10% (w/v) SDS, 0.1% bromophenol blue, pH adjusted to 6.8. The samples 
were reduced by adding 2.5% P-mercaptoethanol and heating at 85° C for two minutes 
immediately prior to loading. 5-50 pg of sample was loaded into each well, and 
electrophoresis was carried out at 25 mA starting and 8 mA ending current (125V 
constant) for approximately 60 minutes. The gels were subsequently stained in a solution 
containing 0.06% Coomassie Blue, 50% methanol, and 7% glacial acetic acid in ultrapure 
water for approximately 12 hours, and then de-stained for approximately 16 hours in a 
destain solution containing 10% methanol and 7% glacial acetic acid in ultrapure water. 
Gels were then permanently fixed on a slab gel drier (SGD 4050 Slab Gel Dryer, Savant 
Instruments, Inc., Holbrook, NY).
Electrophoresis was also carried out on 10-well 12% Bis-Tris-HCl (Bis[2- 
hydroxyethyl]imino-tris[hydroxymethyl]methane-HCl) buffered (pH 6.4) polyacrylamide 
gels (NuP%e ™Bis-Tris gels) in accordance with the manufacturer’s protocol 
(Invitrogen-Nupage). The lower chamber ruiming buffer was composed of 1.00 M MES, 
1.00 M Tris base, 69.3 mM SDS, and 20.5 mM EDTA (ethylenediaminetetraacetic acid). 
The composition of the upper (iimer) buffer chamber running buffer was the same as for
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the lower, with the addition of 0.25% of Nupage™ antioxidant (Invitrogen) containing 
dimethylformamide and sodium bisulfite. The sample buffer (pH 8.5) was composed of 
40% glycerol, 6.82% tris base, 6.66% tris HCl, 8% LDS (lithium dodecyl sulfate), 0.06% 
EDTA, 0.075% Serva Blue 0250 stain, and 0.025% phenol red. Two gels were run 
simultaneously. 3>5pg of sample was loaded onto each well, and electrophoresis was 
carried out at 200 V constant voltage for approximately 30 minutes. Gels were then 
shaken in fixative consisting of 50% methanol, 10% glacial acetic acid and 40% ultrapure 
water for 10 minutes, stained in colloidal blue stain solution and destained in ultrapure 
water according to the protocol provided by the manufacturer (NuPage ™ Colloidal Blue 
Stain Kit-lnvitrogen). Gels were stored in 20% ammonium sulfate solution at 4 °C until 
drying.
Cytological Analysis 
Cytological characterization of apoptosis was performed by Jarvis and colleagues 
as previously described (1997). To examine cells for the apoptotic morphological 
changes, they were stained with 20% Wright-Giemsa stain and assessed for the 
expression of nuclear and cytoplasmic condensation, membrane blebs, apoptotic nuclear 
bodies and cell shrinkage by light microscopy (LM). At least four 50-cell fields were 
scored.
To detect apoptotic DNA damage, cells that were prepared and fixed as described 
(Jarvis et al., 1997) were stained to detect broken DNA by treatment with TdT in the 
presence of fluorescein isothiocyanate-dUTP (FITC-dUTP) and then counterstained for 
intact DNA with propidium iodide. At least four 50- cell fields were scored by
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fluorescence microscopy (FM) by evaluation of increased direct fluorescence of end- 
labeled double-stranded DNA.
Statistical Analysis
Analysis of variance (ANOVA) and the Bonferroni analysis for multiple 
comparisons were used for statistical evaluation of the data. A P-value of < 0.05 was 
considered significant. Unless noted otherwise, data are expressed as the mean ± SEM of 
groups consisting of 4 observations. Unless otherwise noted, each experiment was 
performed independently at least 3 times and representative results are reported.
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RESULTS
Previously reported results using MMQ (rat pituitary adenoma) and C6 (rat 
glioma) cells determined that TES is an effective inhibitor of proliferation in 
neuroendocrine tumor cells (Spangelo et al., 1998, 2000). Because TES exhibited these 
anti-proliferative abilities on MMQ and C6 cells, and because it is a known stimulator of 
T cell-mediated immunity, we examined its capabilities as an inhibitor of human 
leukemia cell proliferation.
Continuous Culture of 
HL-60 cells
In continuous culture, HL-60 cells proliferated rapidly, doubling in concentration 
(cells/mL) every 24-30 hours (Eig 4). Cell viabilities consistently remained above 95% 
during the culture period (data not shown). Cells were removed from culture and assayed 
during the logarithmic phase of proliferation that occurred at 24-96 hours.
Effects of TE5 on HL-60 Cell Proliferation:
Dye Exclusion and MTT Assays
TES (100-800 pg/mL) suppressed the proliferation of HL-60 cells during 24-72 
hours of exposure (Eig 5), with cell viability being reduced to 60% within 48 hours as
38
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determined by the viable dye exclusion assay (Table 1). At 400 pg/mL TFS, cell 
proliferation was inhibited by 50% (EDso) and 800 pg/mL TF5 consistently achieved 
maximal inhibition. This anti-proliferative effect increased with time, demonstrating 
maximal inhibition at 72 hours of incubation (Fig 6).
In the MTT assay, TF5 was less effective as an anti-proliferative agent at higher 
cell densities (Fig 7). While all concentrations of TF5 inhibited proliferation at initial 
plating densities of 5 and 10 x 10^  cells per well, higher concentrations of TF5 were 
required to significantly inhibit cell proliferation at greater cell densities. An initial 
plating density of 20x10  ^cells/well allowed was chosen for all subsequent MTT reaction 
assays. This initial density allows a clear TF5 dose-response with an EDso at 
approximately 400 pg/mL and maximal Inhibition at 800 pg/mL, consistent with the 
viable dye exclusion assay.
To examine the mechanism by which inhibition was effected, we tested the ability 
of HL-60 cells to rebound from 24 hours of pretreatment with 800 pg/mL of TF5 as 
measured by the viable dye exclusion assay. Cells that had been pretreated with TF5 and 
then rinsed were re-cultured in vehicle and compared to cells cultured only in vehicle, 
and cells cultured in vehicle with 800 pg/mL of TF5. Pretreatment with TF5 (24 hours) 
produced the same capacity for suppressed proliferation as continual treatment (Fig 8). 
These results suggested that TF5 induced its anti proliferative effects within 24 hours. Its 
removal did not diminish the observed inhibition. Because of this, we hypothesized that 
the cells metabolize a consumable factor found in TF5. To test this hypothesis, the 
supernatant from cells treated with 800 pg/mL TF5 for 24 hours was applied as a 
conditioned medium to a naive cell culture (HL-60-conditioned TF5). This was compared
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to cells cultured in vehicle, 800 pg/mL TFS, and 800 pg/mL TFS dissolved in HL-60 
conditioned medium. The proliferation of cells treated with TFS-conditioned medium 
was similar to that of cells cultured in vehicle. In contrast, the effects of treatment with 
800 pg/mL TFS were the same in both vehicle and HL-60-conditioned medium (Fig 9). 
These preliminary results support our hypothesis.
Effects of TFS on HL-60 Cell Proliferation:
Clonogenic Assay
Cell proliferation can also be measured using a single layer soft agar system to 
determine the capacity of the cells to form colonies. In contrast to the viable dye 
exclusion and MTT assays, clonogenic potential is a direct measure of cell viability and 
proliferative capacity. Therefore, the clonogenic potential of HL-60 cells was tested in 
the presence and absence of TFS. Initial experiments demonstrated that the clonogenic 
potential of HL-60 cells was dependent on initial cell number (Fig 10). We chose 300 
cells/well as the initial cell plating density in all subsequent experiments because this cell 
concentration allowed concentration-dependent effects of TFS similar to those observed 
in the viable dye exclusion and MTT assays.
The ability of TFS to inhibit the clonogenic potential of HL-60 cells was tested. 
Cells were pretreated with concentrations of TFS ranging from 100-800 pg/mL. TFS 
reduced the ability of HL-60 cells to form colonies in a dose dependent manner. The 
dose producing S0% inhibition (EDso) was 400 pg/mL and 800 pg/mL was maximally 
effective, as with the MTT assay (Fig 11). To determine the minimum incubation period 
required for inhibition of colony-forming potential, pretreatment time course experiments
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were conducted. Exposure to 400 pg/mL for as little as 4 hours produced inhibition of 
colony formation. Exposure to 800 pg/mL of TFS for 4 hours significantly inhibited 
colony formation, and 8 hours essentially completely inhibited HL-60 clonogenic 
potential (Fig 12).
Effect of zVAD-fmk on TFS Inhibition 
of HL-60 Cell Proliferation 
The mechanism of inhibition was investigated using the known apoptosis 
inhibitor, z-Val-Ala-Asp-CHjF (zVAD-fmk), a cell-permeable, broad-spectrum 
irreversible caspase inhibitor. We compared the ability of zVAD-fmk to reverse the 
effects of TFS to its ability to reverse the effects of etoposide, a known apoptosis inducer. 
In these experiments, zVAD -fmk was not able to reverse the effects on HL-60 cells of 
either TFS or etoposide (data not shown). Since it has been recently reported that zVAD- 
fmk does not universally protect cells from apoptosis, (Zhang, Sheng and Loh, 1999; 
Amarente-Mendes et al., 1998), these experiments were repeated using another known 
apoptosis inducer that acts through a different mechanism, sphingomyelinase (Smase) 
(Fig 13). Again neither the effects of TFS nor of Smase were reversed by zVAD-fink. 
Therefore, cytological analyses were performed to determine whether TFS treatment 
induces the appearance of morphological and cytoarchitectural features of apoptosis in 
HL-60 cells.
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Effects of TF5 on HL-60 Cell Proliferation:
Cytological Analysis 
Cells were treated with vehicle or excessive doses of known apoptosis inducers 
(ceramide, sphingosine) or maximal doses of TFS and then examined for membrane 
blebbing, nuclear and chromatin condensation, apoptotic nuclear bodies and cell 
shrinkage by light microscopy (LM). The terminal deoxynucleotidyl transferase dUTP 
nick-end labeling (TUNEL) assay was used to assess by fluorescence microscopy (FM) 
the induction of apoptotic DNA damage in the cells. The cytological effects of lipid 
messengers known to induce apoptosis (Jarvis et al., 1997) are presented in Table 2. 
These compounds caused the appearance in HL-60 cells of cytological features (i.e. 
membrane blebbing, DNA damage) characteristic of apoptosis. In contrast, the data 
presented in Table 3 shows that treatment with maximal doses of TF5 did not induce 
cytological features associated with apoptosis. These experiments confirm that apoptosis 
is not involved. Rather, TFS appears to induce cytostasis in HL-60 cells.
HPLC Analysis of TFS: Reverse Phase 
TFS can be separated on isoelectric focusing gels into several components. Three 
peptide components. Ta,, TP4, and MB-3S have been purified and sequenced. None of 
these purified thymosin peptides (Tat, T^4, MB-3S) had any effect on HL-60 cells in 
pharmacological doses (Fig 14). Therefore, TFS was further purified using reverse- phase 
HPLC (rpHPLC). Of the sixty resulting fractions, only fraction 24 demonstrated 
consistent inhibition of HL-60 cell proliferation (Fig IS). As an anti proliferative agent, 
fraction 24 was ten times more potent than TFS (Fig 16).
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HPLC Analysis of TF5: Size Exclusion 
Due to the limited amount of sample produced by rpHPLC we were unable to 
obtain sufficient quantities for thorough analysis and purification of TFS-fraction 24. 
Therefore, TFS was also separated by size exclusion gel permeation HPLC. Because TFS 
contains a number of small peptides, a standard curve was generated using proteins in the 
molecular weight range of lOSO Da to 66 kDa (Fig 17). None of the resulting TFS 
fractions consistently demonstrated significant inhibition of HL-60 cell proliferation (Fig 
18).
Gel Filtration Chromatography Analysis of TFS 
To more effectively purify useful quantities of its anti proliferative activity, TFS 
was separated on the basis of molecular size by gel filtration chromatography on a 
Sephadex G-SO gel bed with a flow rate of 1.4 mL/min. The standard curve for protein 
standards in the molecular weight range 1060 Da to 24 kDa is shown in Fig 19. 
According to this standard curve, the most active TFS firaction (fraction S) corresponds to 
approximately 20 kDa molecular weight. Since TFS contains only peptides of less than 
IS kDa, it is possible that oligomerization of component peptides may occur in the 
biologically active form of the extract. In Fig 20, the protein concentrations are compared 
to the anti-proliferative activity of the fractions resulting from the separation of TFS (SO 
mg) by gel filtration chromatography.
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Gel Electrophoresis of TF5 and Biologically 
Active TF5 Fractions 
Molecular weight estimates of the TFS fractions were performed under reducing 
and denaturing conditions using polyacrylamide gel electrophoresis. Biologically active 
TFS gel filtration chromatography fractions were separated on Tris- glycine SDS- PAGE 
gels. Mobilities were compared to those of wide- range molecular weight protein 
standards (2.S kDa -  200 kDa) shown in Fig 21. The behavior of TFS and two less 
purified thymus extract preparations ( TP12900S86, TP2169066) are also shown. The 
most predominant band of the active fraction on these gels corresponds to a molecular 
weight estimate of less than 14 kDa (Fig 22). Bis- Tris gels were used to achieve better 
separation of very low molecular weight species. Mobilities were compared to those of 
wide- range molecular weight protein standards (2.S kDa -  200 kDa). The standard curve 
for these gels is shown in Fig 23. Fig 24 shows that the TFS fractions are still 
heterogeneous, and further purification is required before sequencing can be attempted. 
Four predominant bands are present in the molecular weight range 5000-15000.
Effects of Other Thymic Extract Preparations 
On HL-60 Cell Proliferation:
Comparison to TF5
To determine whether the anti- tumor activity present in TF5 can be isolated from 
other thymus extracts, its effects were compared to those of less purified bovine thymus 
extract preparations. Thymus preparations (TP, TAP) inhibited the proliferation of HL-60 
cells in a manner similar to that of TF5 (Fig 25). Reverse-phase HPLC fractions of one
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
45
thymus acetone preparation, TAP, contain both inhibitory and stimulatory factors (Fig 
26). The Lowry protein profile of TAP fractions indicates that the area of greatest 
inhibition of tumor cell proliferation corresponds to the protein peak, whereas the highly 
stimulatoiy activity precedes the protein peak. TAP fraction 20 inhibited HL-60 cell 
proliferation by as much as 80%, whereas fraction 10 induced substantial proliferation in 
the cells. A dose response comparing the potency of TAP fraction 20 in HL-60 cell 
inhibition to that of TF5 and the parent extract (TAP) is shown in Fig 27. As with TF5, 
further separation of the anti-proliferative activity by size-exclusion HPLC was 
unsuccessful (data not shown).
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DISCUSSION
Thymosin fraction 5 is a partially purified protein extract of the bovine thymus 
that contains at least 30-40 heat-stable polypeptides. It is frequently used as a 
replacement for an intact thymus in various in vitro and in vivo models. TFS stimulates 
multiple immune functions and exhibits anticancer effects, making it attractive as a 
potential source of medications to treat immune disorders and cancers. We have 
previously reported (Spangelo et al., 1998) that TFS inhibits the proliferation of the rat 
pituitary adenoma MMQ and rat C6 glioma cell lines in vitro, but induces only a modest 
suppression of proliferation in the CRL7686 human melanoma cell line. TFS has also 
been shown to thwart the proliferation of certain murine leukemia cells (Khaw et al., 
1973; Schultz et al., 1976; Petro et al., 1982) and human acute lymphoblastic T cell 
leukemia cells in vitro (Ho et al., 1983,1983a). Furthermore, TFS normalized the in vitro 
immune responses of human T cells from leukemia patients (ALL, CLL, AML) (Schafer, 
et al., 1976).
The in vitro effects of TFS on human acute myelogenous leukemia cell 
proliferation have not been tested, however, and the presumed activity in TFS that is 
responsible for the inhibition of tumor cell proliferation has not been identified. In 
addition, the mechanism of TFS inhibition of myelogenous leukemia cells has not been
46
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determined. Therefore, we studied the effects of TFS on HL-60 human acute 
myelogenous leukemia cells.
HL-60 Cell Culture
The HL-60 cell line responded well in continuous suspension culture under the 
conditions described, maintaining high cell viability (>90%) throughout the culture 
period. The cell-doubling time was 24-30 hours during the logarithmic growth phase. 
HL-60 cells also formed colonies spontaneously in soft agar in a manner that was 
dependent on initial cell plating density.
Effects of TFS on HL-60 Cell Proliferation:
Viable Dye Exclusion and MTT Assays 
We found that TFS inhibited the proliferation of HL-60 cells in vitro in a dose, 
time and cell number- dependent manner. As with the MMQ and C6 neuroendocrine 
tumor cell lines (Spangelo et al., 1998), the suppression of HL-60 proliferation was 
accompanied by only a modest reduction in cell viability. The TFS EDso for HL-60 cell 
growth suppression was approximately 400 pg/mL, and maximal inhibition (< 20% of 
control cultures) was achieved with a concentration of 800 pg/mL at 72 hours of 
incubation. In contrast, 1000 pg/mL of TFS only moderately suppressed CRL7686 
human melanoma cell proliferation (60% of control cultures at 1000 pg/mL), with an 
EDso of approximately 700 pg/mL. As with the MMQ, C6 and CRL7686 cells, none of 
the purified thymosin peptides (Ta,, Tp4, MB-3S) had any effect on the proliferation of 
the HL-60 cells. Together, these results indicate that TFS may not exert a non-specific 
effect in the inhibition of HL-60 cell proliferation.
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TFS had less effect on HL-60 proliferation at higher initial cell densities. 
Depending on the cell density, concentrations as low as 100 pg/mL significantly 
suppressed HL-60 cell growth. However, concentrations below 600 pg/mL did not block 
the proliferation at an initial plating density of 30x10* cells/well. The effects of low 
concentrations of TFS were also increasingly less dramatic with time, suggesting that an 
anti-TFS activity accumulates in the HL-60 cell cultures. Similar effects were observed in 
the MMQ cell line, and we found that S0% MMQ-conditioned medium largely reversed 
the TFS inhibition of MMQ cells (Spangelo et al., 1998), supporting the hypothesis that 
MMQ cells release a factor that interferes with TFS inhibition of cell growth. However, 
in characterizing the HL-60 cell line, Gallagher and colleagues (1979) found that HL-60- 
conditioned medium does not stimulate the in vitro proliferation or clonogenic potential 
of normal bone marrow cells or leukemic leukocytes. In a later study, this group analyzed 
the ability of HL-60 conditioned medium and concentrated HL-60 cell extracts to 
stimulate their own clonogenic potential. None of the HL-60 conditioned preparations 
were able to stimulate the colony formation of HL-60 cells or normal bone marrow cells 
(Ruscetti et al., 1981). This indicates that HL-60 cells may not release an autonomous 
growth factor that interferes with the action of TFS.
Additionally, we found that HL-60 cell counts and MTT-derived optical density 
(OD) units were significantly reduced within 24 hours in TFS treated cultures as 
compared with control cells. TFS suppression of HL-60 cell proliferation was not 
diminished by the removal of TFS after the initial incubation period. Further, when TFS 
in medium was exposed to HL-60 cells for 24 hours, it was not able to inhibit the
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proliferation of naïve cell cultures. It appears that the HL-60 cells metabolize a 
consumable factor found in TF5.
Effect of TF5 on HL-60 Cell Proliferation:
Clonogenic Assays
In semi-solid medium such as agar, HL-60 cells form spontaneous colonies 
without the necessity for exogenous growth factors (Gallagher et al., 1979; Ruscetti et al., 
1981). TFS inhibited the cloning potential of HL-60 cells in a dose-dependent manner, 
suggesting that an activity in TFS prevents the occurrence of HL-60 colony formation in 
agar. As with the MTT and viable dye exclusion assays, the TFS EDso for the inhibition 
of colony formation was approximately 400 pg/mL, and maximal inhibition was 
achieved with a concentration of 800 pg/mL. Exposure to 400 pg/mL of TFS for as little 
as 4 hours retarded colony formation and 800 pg/mL of TFS for 8 hours was sufficient to 
completely inhibit HL-60 clonogenic potential. We suggest that a thymic peptide may 
prevent metastatic growth of human leukemia cells in situ. The results of the clonogenic 
assay are consistent with those obtained using the MTT and trypan blue exclusion assays, 
both of which demonstrated a decrease in cell viability and proliferation in the presence 
ofTFS.
Mechanism of TFS Inhibition of 
HL-60 Cell Proliferation 
We used known inducers (etoposide, sphingomeylinase) and inhibitors (zVAD- 
fink) of apoptosis to study the mechanism of this inhibition. The broad-spectrum caspase 
inhibitor zVAD-fink failed to reverse the effects of TFS and the apoptosis inducers
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etoposide (VP-16) and sphingomyelinase. That is, the clonogenic potential of the cells 
was not protected in any of the test groups. Since it has been recently reported that (1) 
zVAD-fink fails to protect HL-60 cells from other apoptosis inducers (Zhang, Sheng and 
Loh, 1999) and (2) zVAD-fink did not rescue the clonogenic potential of HL-60 cells 
from apoptosis induced by etoposide, staurosporine and Actinomycin-D (Amarente- 
Mendes et al., 1998), these experiments were repeated using another known apoptosis 
inducer that acts through a distinct mechanism, sphingomyelinase (Smase). Again neither 
the effects of TFS nor of Smase were reversed by zVAD-fmk. Therefore, cytological 
analysis by light microscopy and the TUNEL assay were used to further investigate the 
mechanism of TFS action on HL-60 cells. These experiments confirm that apoptosis is 
not involved. Thus, TFS appears to induce cytostasis in HL-60 cells. This is in contrast 
to our observations with the MMQ and C6 neuroendocrine cell lines, in which apoptosis 
was the apparent mechanism of TFS inhibition. The data in our study may demonstrate a 
new biological property of TFS: the inhibition of cell proliferation and the induction of 
cytostasis in human myeloblastic leukemia cells in vitro.
Identification of TFS Anti-Proliferative 
Activity
We believe that the anti-proliferative activity in TFS is due to one or more peptide 
components. On the basis of dry weight, TFS is 99% protein with a small amount of 
carbohydrate and essentially no nucleotide (Hooper et al., 197S). Several previously 
purified components of TFS (i.e. Ta,, Tp4, MB-35) had no discernible effect on HL-60 
cell proliferation. Therefore, TFS was further fractionated using rpHPLC. Further 
purification of TFS into sixty one-minute fractions by rpHPLC resulted in one fraction
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(fraction 24) that significantly inhibited HL-60 cell proliferation. It is noteworthy that 
none of the previously purified thymosin peptides elute in this fraction. Fraction 24 was 
ten times more potent than TF5, indicating substantial purification of the anti­
proliferative activity. The rpHPLC process did not provide enough material for further 
purification, but it does support our argument that the observed inhibition of HL-60 cells 
is due to an activity present in TF5 rather than a non-specific effect (i.e. not all fractions 
affected the cells).
To generate useful quantities of the anti-proliferative activity in TFS, it was 
fractionated by size exclusion gel permeation HPLC. None of the resulting fractions 
consistently demonstrated significant inhibition of HL-60 cell proliferation. This may 
indicate that a component necessary for biological activity was removed, or that the 
fractionation process modified the active molecule.
To avert this possibility and to generate larger sample quantities, we separated 
substantial quantities of biologically active TFS fractions on the basis of molecular size 
by gel filtration column chromatography on a Sephadex gel bed. Although the fabrication 
process for TFS extract excludes proteins larger than IS kDa, we separated biologically 
active fractions of TFS corresponding to approximately 20 kDa that inhibited HL-60 cell 
proliferation by more than 80%. This may suggest that oligomer formation occurs in a 
biologically active form of thymosin components. We also obtained moderately active 
(i.e. fraction 34, Fig 20) fractions of approximately 1200- ISOO MW. Data obtained by 
Hooper and colleagues (1975) also suggested the presence of subunits in purified 
fractions of TFS. They purified a moderately active molecule with a calculated molecular 
weight of 12,200 from TFS. When this preparation was subjected to gel filtration under
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reducing and denaturing conditions, it eluted as two protein peaks of MW 3200 and 2400, 
suggesting that the preparation is composed of polypeptide subunits.
Estimates of molecular weight were performed under reducing and denaturing 
conditions on polyacrylamide gels. Separation on 4- 20% Tris-Glycine polyacrylamide 
gels did not substantially resolve the fractions, which migrated as a dense group of bands 
in the range of 6 kDa to 22 kDa. This suggests that the fractions may contain multiple 
peptides of similar molecular weight. Pre-cast 12% Bis-Tris polyacrylamide gels were 
used to achieve better separation of very low molecular weight components. On these 
gels, TF5 and active fractions of TF5 show a strong band density at approximately 6 kDa, 
and three other predominant bands in the 5000-15000 molecular weight range.
To determine whether the anti-tumor activity present in TF5 can be isolated from 
other thymus extracts, we compared the anti-proliferative effects of TF5 on HL-60 cells 
to the effects exerted by less purified bovine thymus preparations. Thymus acetone 
preparations (acetone precipitation) inhibited HL-60 cell proliferation in a dose- 
dependent manner. One such preparation, TAP, was subjected to reverse-phase HPLC. 
The activity profile for these fractions has two regions of inhibition, and a large peak of 
stimulation. The area of greatest anti-proliferative activity, TAP fraction 20, corresponds 
to the protein peak, while the growth-stimulating activity (fraction 10) precedes it. We 
hypothesized that separation of the two activities would allow more pronounced 
concentration-dependent effects of the anti-proliferative action of TAP fiaction 20 (TAP- 
20) on HL-60 cells. TAP-20 was 40 times more effective than TAP in the inhibition of 
HL-60 cell proliferation. As with TF5, we were unable to purify this activity further by 
size-exclusion HPLC. Given the substantially concentrated anti proliferative activity in
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this preparation, alternative methods of purification (i.e. gel filtration column 
chromatography) seem warranted. Likewise, two-dimensional isoelectric focusing on 
SDS-PAGE gels would provide better resolution of the biologically active TF5 fractions.
Conclusions
We conclude that TF5 inhibits the proliferation of HL-60 human myelogenous 
leukemia cells in a dose and time-dependent manner in vitro. This inhibition does not 
seem to be due to a nonspecific effect. Nor does it appear that a factor secreted by the 
cells disrupts the effects of TF5. Our observations suggest the HL-60 cells metabolize a 
consumable factor in TF5. Thymosin also inhibited the colony-forming potential of HL- 
60 cells in soft agar. We suggest that a thymic peptide may prevent metastatic growth of 
human leukemia cells in situ. TF5 apparently does not induce apoptosis in the HL-60 
cells, but it may induce cytostasis. Thus, our observations may demonstrate a new 
biological property of TF5: the inhibition of cell proliferation and colony-forming 
potential, and the induction of cytostasis in HL-60 human myelogenous leukemia cells in 
vitro.
Useful quantities of a low molecular weight, biologically active TF5 activity can 
be separated by gel filtration chromatography. Further purification is necessary to 
identify and sequence the active component(s). None of the previously purified thymosin 
peptides elutes in the biologically active rpHPLC fiaction of TF5. However, TF5-like 
activity was observed in several thymus acetone powders that are less purified than TF5.
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These studies suggest that a thymic hormone immune surveillance mechanism 
may suppress the onset of certain types of leukemia. The isolation of the active thymosin 
peptide may provide a novel treatment strategy for the management of certain leukemias.
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VeUde %.6±0l5 % 9±a7 97^±a4
100 ^ inL 93L8±09 % 9±a7 % 4±a6
400pg/mL 9L5±L8 9L2±aS 9I5±a9
OOOpg/mL %4±3.0 614±&2 6i2±S3
Table 1. Effect of TF5 on the viability of HL-60 human myelogenous leukemia celts. 
2.4 xIO  ^HL-60 cells were exposed to TF5 for 72 hr. Results are the averages of 
percent viability from three independent experiments.
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%  V e h ic le  C on tro l
Vehicle 1 +/-1% 2 +/-1%
Ceramide 5 +/- 2% 27 +/-1%
Sphingosine 11+/. 4% 89+/-1%
Table 2. Cytological Effects of Sphineolipid Messengers on HL-60 Cells. Cells were 
exposed to vehicle or ceramide or sphingosine (10 pM) for 9 hr. DNA damage was 
visualized by fluorescence microscopy (FM) after staining with FITC-dUTP in the 
presence of TdT. Morphologic features of apoptotic cell death were observed by light 
microscopy (LM) after staining with conventional Wright-Giemsa. Values are 
expressed as the mean ± SEM of four determinations.
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% V d iic le  C on tro l
CONTROL 3 +/-1% 2 +/-1%
TF5 24 Hrs. 3 +/-1% 2 +/- 1%
TF5 48 Hrs. 5 +/- 2% 1 +/- 1%
TF5 72 Hrs. 4+/-l% 4 +/- 2%
Table 3. Cytological Effects of TF5 on HL-60 Cells. Cells were exposed to a maximal 
dose of TF5 for 72 hr. Cells exhibiting DNA damage were visualized by fluorescence 
microscopy (FM) after staining with FITC-dUTP in the presence of TdT.
Morphologic features of apoptotic cell death were observed by light microscopy 
(LM) after staining with conventional Wright-Giemsa. Values are expressed as the 
mean ± SEM of four determinations.
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THYMUS DEPENDENT SENESCENCE OF IMMUNITY IN MAN
D eeoses of Aging 
(Canoer.AuloinvTu«
bnm nty %»
Dseoses of Chidhood 
(Cancer, kifectious Diseases)
AGE IN YEARS
Figure 1. Thvmus Dependent Senescence of Immunity in Man. Schematic showing 
the relationship between decreased thymus function, thymic hormone levels, and 
thymus-dependent immunity.
^Reprinted from Goldstein et al., 1975, by permission of the author.
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Figure 2. Schematic showing the locations of thvmosin peptides in the thvmus 
Gland. TFS and TF6 have been found throughout the cortex and medullary 
epithelial cells (Hirokawa, McClure, and Goldstein, 1982; Schuurman et al, 1985).
Adapted from Janeway and Travers, 1994
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Figure 3. Principle hypothesis of this study. Because TFS generally stimulates 
thymus-dependent inununity, and because ant-tumor immunity is under thymic 
control, we hypothesized that TFS would directly inhibit leukemia cell proliferation.
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Figure 4. Proliferation of HL«60 human myelogenous leukemia cells in continuous 
suspension culture. HL-60 cells (15 x  10^  cells/well) were cultured in a humidified 
atmosphere of S% €02-95% air at 37**C in phenol-free RPMI-1640 supplemented 
with 10% heat-inactivated fetal bovine serum, sodium pyruvate, nonessential amino 
acids and antibiotics. Cell numbers were determined by standard microscopy every 
24 hr. The mean doubling time for the data shown is 28.5 hr. The data are expressed 
as the mean ± SEM of groups consisting of four observations.
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Figure S. TPS inhibits HL-60 human myelogenous leukemia cell proliferation. 
Cultured HL-60 cells (7S x 10^  cells/well) were exposed to either vehicle (complete 
RPMI-1640) or different concentrations of TPS for 24-72 hr, and cell concentrations 
were determined by standard microscopy and viable dye exclusion.
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Figure 6. TF5 inhibits HL-60 human myelogenous leukemia cell proliferation: effect 
of incubation period. Cultured HL-60 ceils (20 x 10^  cells/well) were exposed to 
either vehicle (complete RPMI-1640) or different concentrations of TF5 for 24-72 hr, 
and cell proliferation was determined by the MTT viability assay.
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Figure 7. TF5 inhibits HL-60 human myelogenous leukemia cell proliferation: effect 
of cell number. Cultured HL-60 cells (5-30 x 10^  cells/well) were exposed to either 
vehicle (complete RPMI-1640) or different concentrations of TF5 for 72 hr, and cell 
proliferation was determined by the MTT viability assay.
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Figure 8. TPS inhibits HL-60 human myelogenous leukemia cell proliferation: effect 
of pretreatment period. Cultured HL-60 cells (80 x 10^  cells/mL^ were pretreated 
with 800 pg/mL TPS for 24 hr and cultured in complete RPMI-1640, or cells were 
exposed to either vehicle or 800 pg/mL TPS. Cell concentrations were determined by 
standard microscopy and viable dye exclusion at 24 to 96 hr.
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Figure 9. TF5 inhibits HL-60 human myelogenous leukemia cell proliferation: effect 
of HL-60 conditioning of TFS. Cultured HL-60 cells (80 x 10^  cells/well) were either 
treated with vehicle (complete RPMI-1640), TFS (800 pg/mL), or TFS that was 
removed from HL-60 cells following a 24 hr incubation period. In addition, HL-60 
cells were exposed to TFS that was diluted in a 24 hr HL-60 cell- conditioned 
medium. Cell concentrations were determined by standard microscopy and viable 
dye exclusion.
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Figure 10. HL-60 human myelogenous leukemia cell colonv-forming potential in soft 
agar is dependent on initial cell plating density. Cultured HL-60 cells were plated at 
varying initial cell numbers and then cultured for 14 days in agar.











Figure 11. TFS inhibits the cionogenic potential of HL-60 human myelogenous 
leukemia cells: effect of TFS dose. Cultured HL-60 cells HOO x 10^  celWml.) were 
pretreated with 100-800 pg/mL TFS for 24 hr and then cultured for 14 days in agar 
(300 cells/well).
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
71





Figure 12. TFS inhibits the cionogenic potential of HL-60 human myelogenous 
leukemia cells: effect of pretreatment period. Cultured HL-60 cells (100 x 10^  
cells/mL) were pretreated with 800 pg/mL TFS for 4,8 or 24 hr and then cultured for 
14 days in agar.














Figure 13. TFS inhibits the cionogenic potential of HL-60 human mveloeenous 
leukemia cells: effect of pre-incubation of HL-60 cells with an apoptosis inhibitor. 
Cultured HL-60 cells (100 x 10^  cells/mL) were pretreated with 800pg/mL TFS for 
24 hr or pre-incubated in the presence of lOOpM zVAD-fink (in DMSO) and then 
pretreated with 800pg/mL TFS for 24 hr or 200mU sphingomyelinase for 9 hr. The 
cells were then cultured for 14 days in agar. Colony numbers were determined by 
microscopy.
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Figure 14. Effect of purified thvmosin peptides on HL-60 human myelogenous 
leukemia cell proliferation: comparison to TFS. Cultured HL-60 cells f20 x 10^  
cells/well) were exposed to vehicle (RPMI-1640, supplemented) or TF5, Toi, Tp< or 
MB-3S for 72 hr. Only TFS significantly suppressed cell proliferation. The data are 
expressed as the mean ± SEM of groups consisting of four observations.














Figure IS. Effect of HPLC fraction 24 on HL-60 human myelogenous leukemia 
cell proliferation: comparison to TFS. Cultured HL-60 cells (20 x 10^  cells/well) 
were exposed to vehicle (complete RPMI-1640), fraction 24 or TFS for 72 hr, and cell 
proliferation was determined by the MTT viability assay. Inset shows the UV profile 
at 280nm of the HPLC separation of TFS.
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Figure 16. Effect of HPLC fraction 24 on HL-60 human myelogenous leukemia cell 
proliferation: comparison to TFS. Cultured HL-60 cells (20 x 10^  cells/well) were 
exposed to vehicle (complete RPMI-1640), fraction 24 or TFS for 72 hr, and cell 
proliferation was determined by the MTT viability assay.
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Figure 17. Protein standard curve for size exclusion HPLC. Retention times are 
plotted against the log of the MW of each protein standard (BSA, trypsin, cytochrome 
c, and bradykinin). The data are expressed as the mean ± SEM of groups consisting of 
three separate sample injections.
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Figure 18. Effect of HPLC fractionated TF5 on HL-60 human myelogenous leukemia 
cell proliferation. Cultured HL-60 cells (20 x 10^  cells/well) were exposed to either 
vehicle (complete RPMI-1640) or different firactions of size exclusion HPLC- 
separated TFS for 72 hr, and cell proliferation was determined by the MTT viability 
assay.
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Figure 19. Protein standard curve for gel filtration chromatography. Distribution 
coefficient (K) values for the protein standards trypsin (MW 24 kOa), cytochrome c 
(MW 12kDa), and bradykinin (MW 1060 Da) are on Sephadex G-SO are shown. The 
flow rate was 1.40 mL/min.


















Figure 20. Effect of gel filtration chromatography- separated TFS fractions on HL-60 
human myelogenous leukemia cell proliferation: comparison to Lowrv protein values. 
TFS was loaded onto the column (50 mg) and 1-minute fractions were collected. 
Protein concentrations were determined by the Lowry method. Cultured HL-60 cells 
(20 X 10^  cells/well) were exposed to individual fractions for 72 hr and cell 
proliferation was determined by the MTT reaction assay. The cell proliferation data 
are expressed as the mean ± SEM of groups consisting of four observations.










Figure 21. Separation of TF5 and thvmus preparations (TPl on 4-20% Tris-glvcine 
gels. TFS (S-SO pg) and thymus preparations (S pg) were reduced with P* 
mercaptoethanol and electrophoresis was carried out at 125V (constant) for 
iq)proximately 60 minutes. Molecular weight standards (MW Stds) are 200 kDa to 2.5 
kDa.
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Figure 22. Separation of TF5 and active TFS gel filtration chromatography fractions 
on 4-20% SDS- PAGE gels. Samples were reduced with P-mercaptoethanol and 
electrophoresis was carried out at 12SV (constant) for approximately 60 minutes.
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Figure 23. Protein standard curve for gel electrophoresis on 12% Bis-tris eels. 
Electrophoresis was carried out at 200V (constant) for approximately 30 minutes.
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Figure 24. Separation of TFS and active TFS pel filtration chromatography fractions 
on 12 %Bis-Tris polvacrvlamide gels. 3-Spg of sample was loaded onto each well, 
and electrophoresis was carried out at 200V (constant) for approximately 30 minutes. 
Fractions 2 and 3 are from the separation of lOmg of TFS. Fractions 4,5, and 6 are 
from the separation of SO mg of TFS.
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Figure 25. Effects of TF5 and thvmus acetone preparations on HL-60 human 
myelogenous leukemia cell proliferation. Cultured HL-60 cells (20 x 10^  cells/well) 
were exposed to vehicle (RPMI-1640, supplemented) or TFS, TAP, TPl or TP-2 for 
72 hr and then proliferation was measured by the MTT reaction assay. All thymus 
preparations inhibited HL-60 cell proliferation. The data are expressed as the mean ± 
SEM of groups consisting of four observations.
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Figure 26. Effect of HPLC-fractionated TAP on HL-60 human myelogenous 
leukemia cell proliferation. Cultured HL-60 cells (20 x 10^  cells/well) were exposed 
to either vehicle (complete RPMI-1640) or different fractions of HPLC separated 
TAP for 72 hr, and cell proliferation was determined by the MTT viability assay. 
Protein concentrations of individual fractions were determined with the Lowry assay. 
Data for HL-60 cell proliferation are expressed as the mean ±SEM of groups 
consisting of four observations.
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Figure 27. Effect of TAP fraction 20 on HL-60 cell proliferation: comparison to TAP 
and TFS. Cultured HL-60 ceils (20 x 10^  cells/well) were exposed to vehicle (RPMI- 
1640, supplemented) or TFS, TAP, or TAP fraction 20 for 72 hr and proliferation was 
measured by the MTT reaction assay. The data are expressed as the mean ± SEM of 
groups consisting of four observations.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
REFERENCES
Asakawa M, Kinoshita Y, Kimura S, Hato F, Wada S, Nishijima T, Kishimoto T, 
Maekawa M (1990) Restorative effects of thvmosin fraction 5 on reduction in 
responsiveness of rat thvmocvtes to allogeneic Ivmphocvtes during bladder tumor 
induction. Cell Mol Biol; 36(3): 265-74.
Aspinall R 119971 Age-associated thvmic atrophv in the mouse is due to a deficiencv 
affecting rearrangement of the TCR during intrathvmic T cell development. 
Journal of Immunology; 158(7): 3037-45.
Attia WY, Badamchian M, Goldstein AL, Spangelo BL (1993) Thvmosin Stimulates 
lnterleukin-6 Production from Rat Spleen Cells in Vitro. Immunopharmacology 
26:171-1796.
Badamchian M, Spangelo BL, Damavandy T, MAcCleod RM, Goldstein AL (1991) 
Complete Amino Acid Sequence Analvsis of a Peptide Isolated from the Thvmus 
that Enhances Release of Growth Hormone and Prolactin. Endocrinology; 128(3): 
1580-1588.
Badamchian M, Wang S-S, Spangelo BL, Damavandy T, Goldstein AL (1990) Chemical 
and biological charactenzatinn of MB-35: a thvmic-derived peptide that 
stimulates the release of growth hormone and prolactin from rat anterior pituitary 
cells. Progress in NeuroEndocrinlmmunology; 3:258-265.
87
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
88
Belcher, AE (1993) Leukemia. In Blood Disorders, Mosby’s Clinical Nursing Series, 
Mosby; St. Louis, MO.
Berthiaume F, Aparicio CL, Eungdamrong J, Yarmush ML. (1999) Aee- and disease- 
related decline in immune function: an opportunity for thvmus-boostine therapies. 
Tissue Engineering Dec; 5(6): 499-514.
Bodey B, Bodey B Jr, Siegel SE, Kaiser HE. (2(X)0) The role of the reticulo-epithelial 
(RE) cell network in the inununo-neuroendocrine regulation of intrathvmic 
lymphopoiesis. Anticancer Research May-Jun; 20(3 A): 1871-88.
Brelinska R, Warchol JB (1982) Receptors for thvmosin fraction V on rat thvmic 
lymphocytes. Experientia 38(5): 618-19.
Cohen GH, Hooper JA, Goldstein AL (1975) Thymosin-induced differentiation of murine 
thymocytes in allogeneic mixed lymphocyte cultures. Annals of the New York 
Academy of Sciences Feb 28; 249:145-53.
Cohen MH, Chretien PB, Ihde DC, Fossiek BE Jr, Makuch R, Bunn PA Jr, Johnston AV, 
Collins SJ, Gallo RC, Gallagher RE (1977) Continuous growth and 
differentiation of human myeloid leukaemic cells in suspension culture. Nature 
Noy; 270: 347-349.
Cowan MJ, Fujiwara P, Wara DW, Ammann AJ (1981) Effect of Thymosin on Cellular 
Immunity in Old Age. Mechanisms of Ageing Deyelopments Jan; 15(1): 29-39.
Shackney SE, Matthews MJ, Lipson SD, Kenady DE, Minna JD; (1979) Thymosin 
fraction V and intensiye combination chemotherapy. Prolonging the suryiyal of 
patients with small-cell lung cancer. Journal of the American Medical Association 
Apr, 241(17): 1813-5.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
89
Cupissol D, Rey A, Goldstein AL, Serrou B (1982) Decrease of tumor growth in mice 
after intravenous thvmosin-treated bone marrow cell injection. Journal of the 
National Cancer Institute Jul; 69(1): 27-31.
Dalton WT Jr, Aheam MJ, McCredie KB, Freireich EJ, Stass SA, Trujillo JM (1988) 
Concise Report: HL-60 Cell Line Was Derived From a Patient With FAB-M2 and 
Not FAB-M3. Blood Jan; 71(1): 242-247.
Dauphinee MJ and Talal N, (1975) Reversible restoration bv thvmosin of antigen- 
induced depression of spleen DNA synthesis in NZB mice. Journal of 
Immunology Jun; 114(6): 1713-6.
Dauphinee MJ, Talal N, Goldstein AL, White A (1974) Thvmosin Corrects the Abnormal 
DNA Synthetic Response of NZB Mouse Thvmocvtes. Proceedings of the 
National Academy of Sciences, USA Jul; 71(7): 2637-2641.
Diezel W, Rentz E, Ermolin G, Sakandelidze OG, Sonnichsen N (1984) Augmentation of 
mitogen-induced interferon production in lymphocytes by thvmosin. 
Experimental and Clinical Endocrinology Jul (1): 99-104.
Dillman RO, Beauregard J, Royston I, Zavanelli MI (1987) Phase II Trial of Thvmosin 
Fraction 5 and Thvmosin Alpha 1. Journal of Biological Response Modifiers, 
6(3): 263-67.
Dillman RO, Beauregard JC, Zavanelli MI, Halliburton BL, Wormsley S, Royston 1 
(1983) In Vivo Immune Restoration in Advanced Cancer Patients After 
Administration of Thvmosin Fraction 5 or Thvmosin a l . Journal of Biological 
Response Modifiers 2(2): 139-49.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
90
Elfenbein GJ, Goldstein AL, Adams JS, Ravlin HM (1980) Thvmosin-induced T cell 
marker expression and enhanced mitogen responsiveness in allogeneic transplant 
recipients Transplantation Feb; 29(2): 113-8.
Erbach GT, Bahr JM (1991) Enhancement of in Vivo Humoral Immunity bv Estrogen: 
Permissive Effect of a Thvmic Factor. Endocrinology Mar; 128(3): 1352-8;
Farah JM Jr, Hall NR, Bishop JF, Goldstein AL, O’Donohue TL (1987) Thvmosin 
fraction 5 stimulates secretion of immunoreactive beta-endorohin in mouse 
corticotropic tumor cells. Journal of Neuroscience Research: 18(1): 140-6.
Forger JM, Cemy J (1976) Thvmic hormone modulation of leukemoeenic virus 
replication. Cancer Research 1976; 36(6): 2048-52.
Gallagher R, Collins S, Trujillo J, McCredie K, Aheam M, Tsai S, Metzgar R, Aulakh G, 
Ting R, Ruscetti F, Gallo R (1979) Characteri/ation of the Continuous. 
Differentiating Mveloid Cell Line fHL-601 From a Patient With Acute 
Promvelocvtic Leukemia. Blood Sep; 54(3): 713-730.
Goldstein AL, Thurman GB, Cohen GH, Hooper JA (1975) Thvmosin: Chemistry. 
Biology, and Clinical Applications. In Biological Activity of Thymic Hormones; 
van Bekkum, DW, ed.; Kooyker Scientific Publications, Rotterdam, The 
Netherlands
Goldstein AL, Guha A, Zatz MM, Hardy MA, White A (1972) Purification and 
biological activity of thvmosin. a hormone of the thvmus gland. Proceedings of 
the National Academy of Sciences, USA, 69:1800-1803.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
91
Goldstein, Slater, White (1966) Preparation, assay and partial purification of a thvmic 
Ivmphocvtopoietic factor. Proceedings of the National Academy of Sciences 
USA, 56:1010.
Hadden EM, Malec P, Sosa M, Hadden JW (1992) Mixed interleukins and thvmosin 
fraction V svnergisticallv induce T Ivmphocvte development in hvdrocortisone- 
treated aged mice. Cellular Immimology Oct 1; 144(1): 228-36.
Hardy MA, Zisblatt M, Levine N, Goldstein AL, Lilly F, White A (1971) Reversal bv 
thvmosin of increased Susceptibility of Inununosuppressed Mice to Molonev 
Sarcoma Virus. Transplantation Proceedings March; 3(1): 926-28.
Hazama S, Hirose K, Enokihara H, Saito K, Komatsu H, Furusawa S, Shishido H, 
Konishi K (1978) In vitro influences of thvmosin (fraction-VI on human 
peripheral blood T lymphocytes. Journal of Medical Science, 5(2): 321-7.
Hirokawa K, McClure JE, Goldstein AL (1982) Age-Related Changes in Localization of 
Thvmosin in the Human Thvmus. Thymus Jan; 4(1): 19-29.
Ho AD, Ma DDF, Price G, Hofibrand AV (1983) Effect of Thvmosin and Phorbol Ester 
on Purine Metabolic Enzvmes and Cell Surface Phenotype in a Malignant T-cell 
line (MOLT-31. Leukemia Research 7(6): 779-86.
Ho AD, Ma DDF, Price G, Hunstein W, Hofibrand AV (1983a) Biochemical and 
Immunological Differentiation of Human Thvmocvtes Induced bv Thvmic 
Hormones. Immunology. 50(3): 471-6.
Hooper JA, McDaniel MC, Thurman GB, Cohen GH, Schulof RS, Goldstein AL (1975) 
Purification and Properties of Bovine Thymosin. Annals of the New York 
Academy Sciences, Feb; 249:125-44.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
92
Hsia J, Sarin N, Oliver JH, Goldstein AL (1989) Aspirin and Thvmosin Increase 
interleukin-2 and Interferon-p Production bv Human Peripheral Blood 
Lvmphocvtes. Immunopharmacology, 17(3): 167-73
Hu SK, Badamchian M, Mitcho YL, Goldstein AL (1989) Thvmosin Enhances the 
Production of IL-lb bv Human Peripheral Blood Monocvtes. Lymphokine 
Research, 8(3): 203-14.
Hu SK, Low TL, Goldstein AL (19811 Modulation of Terminal Deoxvnucleotidvl 
Transferase Activity bv Thvmosin. Molecular and Cellular Biochemistry, Dec; 
41:49-58.
Ikemoto S, Kamizuru M, Hayahara N, Okamaoto S, Wada S, Kishimoto T, Maekawa M 
(1992) Thvmus lvmphocvtes in uraemic rats and the effect of thvmosin fraction 5 
in vivo. Clinical Experiments in Immunology, Feb; 87(2): 220-3.
Ikemoto S, Kishimoto T, Wada S, Hayahara N, Maekawa M (1990) Thvmus lvmphocvtes 
in uraemic rats and the effect of thvmosin fraction 5 in vitro. Clinical Experiments 
in Immunology, Jun; 80(3): 474-7.
Ikemoto S, Sugimura K, Wada S, Yasumoto R, Yamamoto K, Kishimoto T (1999) 
Augmentation of antitumor activity of 5'-deoxv-5-fluorouridine bv thvmosin 
fraction 5 in mouse bladder cancer cells in vitro and in vivo. Cancer Letters Oct 
18; 145(1-2): 1221-6.
Jarvis WD, Kolesnik RN, Fomari FA, Traylor RS, Gewirtz DA, Grant S (1994) Induction 
of apoptotic DNA damage and cell death bv activation of the sphingomyelin 
pathway. Proceedings of the National Academy of Sciences, USA; 91:73-77.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
93
Kendall MD (1991) Functional anatomy of the thvmic microenvironment: Journal of 
Anatomy. Aug: 177:1-29.
Keusch GT, Cruz JR, Torun B, Urrutia JJ, Smith H Jr, Goldstein AL (1987) Immature 
Circulating Lvmphocvtes in Severely Malnourished Guatemalan Children. 
Journal of Pediatric Gastroenterology and Nutrition, Mar-Apr; 6(2): 265-70.
Khaw BA, Rule AH (1973) Immunotherapy of the Dunning leukaemia with thvmic 
extracts: British Journal of Cancer July; 28:288-92.
Kimura S, Ozaki Y, Toyokawa T, Nishio S, Maekawa M, Goldstein AL, Kinoshita Y 
( 1986) Marked Reduction in Percentage of Rosette-Forming Thvmocvtes of Rats 
During Induction of Bladder Tumors and Restorative Effect of Thvmosin in Vitro. 
Journal of the National Cancer Institute Apr, 76(4): 661-7.
Kinoshita Y, Kimura S, Hashimura H, Toyokawa T, Goldstein AL (1986) New System 
Examining Biological Activity of Thvmus Hormone Using Rosette Formation 
Assay of Rat Thvmocvtes. Cellular and Molecular Biology, 32(4): 391-7.
Klein, Goldstein, White (1966) Effects of the Thvmus Lvmphocvtopoietic Factor. Annals 
of the New York Academy of Sciences USA 135,485.
Klein, Goldstein, White (1965) Enhancement of in Vivo Incorporation of Labeled 
Precursors into DNA and Total Protein of Mouse Lvmph Nodes After 
Administration of Thvmic Extracts. Proceedings of the National Academy of 
Sciences, USA 53,812.
Kouttab NM, Goldstein AL, Lu M, Lu L, Campbell B, Maizel AL (1988) Production of 
Human B and T cell Growth Factors is Enhanced bv Thvmic Hormones. 
Inununopharmacology Sep-Oct; 16(2): 97-105.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
94
Lavastida MT, Goldstein AL, Daniels JC (1981) Thvmosin Administration in 
Autoimmune Disorders. Thymus. Feb; 2(4-5):287-95.
Leichtling KD, Serrate SA, Sztein MB (1990) Thvmosin Alpha 1 Modulates the 
Expression of High Affinitv Interleukin -2 Receptors on Normal Human 
Lvmphocvtes. International Journal of Immunopharmacology, 12(1): 19-29
Low and Goldstein (1978) Structure and Function of Thvmosin and Other Thvmic 
Factors. In The Year in Hematology, Silber et al., eds. Plenum Publishing 
Corporation, FRG.
Low and Goldstein, 1984; Thvmosins: Isolation. Structural Studies and Biological 
Activities. In Thymic Hormones and Lymphokines. Goldstein AL ed.. Plenum 
Publishing Corporation, FRG.
Low TLK, Thurman GB, McAdoo M, McClure J, Rossio JL, Naylor PH, Goldstein AL 
(1979) The Chemistry and Biology of Thvmosin. 1. Isolation. Characterization, 
and Biological Activities of Thvmosin a l  and Polypeptide B1 from Calf Thvmus. 
Journal of Biological Chemistry, 254:981-986.
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein Measurement with the 
Folin Phenol Reagent. Journal of Biological Chemistry 1951; 193:265-275.
McGillis JP, Hall NR, Goldstein AL (1988) Thvmosin fraction 5 (TF5) stimulates 
secretion of adrenocorticotropic hormone (ACTH) from cultured rat pituitaries. 
Life Sciences, 42(22): 2259-68.
Murai T, Iwata H, Mori S, Hato F, Kimura S, Kinoshita Y, Wada S, Kishimoto T, 
Makino S, Oohara T, et al (1995) Thvmosin Fraction 5 Does Not Influence
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
95
Urinary Tract Carcinogenesis bv Phenacitin and N-butvl-N-(4-hvdroxvbutvl) 
Nitrosmine in NON/Shi Mice. Oncology Research, 7(3-4): 139-44.
Mutchnik MG, Appelman HD, Chung HT, Aragona E, Gupta TP, Cummings GD, 
Waggoner JG, Hoofiiagle JH, Shafritz DA (1991) Thvmosin Treatment of 
Chronic Hepatitis B: A Placebo-Controlled Pilot Trial. Hepatology, Sep 14(3): 
409-15.
Mutchnik MG, Schafïher JA, Prieto JA, Weller FE, Goldstein AL (1983) Increased 
Thvmic Hormone Responsive Suppressor T Lvmphocvte Function in Chronic 
Active Hepatitis. Digest of Disease Science, Apr; 28(4):328-34.
Naylor PH, Bhakoo HS, Paolini NS, Goldstein AL, Rosen F (1983) Inununomodulation 
of Murine B16 Melanoma Metastasis: Thvmosin. Thvmectomv and Irradiation. 
Thymus, Sep; 5(5-6) 355-61.
Neta R, Schwartz GN, MacVittie TJ, Douches SD (1985) Thvmic hormones in radiation- 
induced immunodeficiency. 1. Induction of mature interleukin 1 responsive cell in 
the thvmus bv thvmosin fraction 5. Cellular Immunology, Sep 94(2): 480-90.
Neta R, Schwartz GN, MacVittie TJ, Douches SD (1985a) Thvmic Hormones in Thvmus 
Recovery from Radiation Injury. Experimental Hematology Today 14:6-13.
Oates, Sztein and Goldstein (1989) Mechanism of action of the thvmosins: modulation of 
Ivmphokines. receptors, and T-cell differentiation antigens. Immunology Series; 
45:273-88.
Okimoto T, Kinoshita Y, Hato F, Toyokawa T, Kimura S, Kinoshita H (1988) Effects of 
thvmosin on soybean lectin responsiveness of thvmic small Ivmphocvte subsets
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
96
from streptozotocin-induced diabetic rats. Cellular and Molecular Biology, 34(5): 
465-72.
Pazmino NH, Ihle JN, Goldstein AL (1978) Induction in Vivo and in Vitro of Terminal 
Deoxvnucleotidvl Transferase bv Thvmosin in Bone Marrow Cells from Athvmic 
Mice. Journal of Experimental Medicine 1978 Mar; 147(3): 708-18.
Petro TM, Chien G, Watson RR (1982) Alteration of cell-mediated immunity to Listeria 
monocytogenes in protein-malnourished mice treated with thvmosin fraction V. 
Infectious Immunology, 37(2): 601-8.
Petro TM, Watson RR (1982a) Resistance to L1210 Mouse Leukemia Cells in 
Moderately Protein-Malnourished BALB/c Mice Treated in Vivo with Thvmosin 
Fraction V. Cancer Research, Jun; 42(6): 2139-45.
Raven and Johnson, (1992) The Immune System. In Biology, 3"* ed., Mosby Year Book 
Incorporated, St. Louis, MO.
Ruscetti FW, Collins SJ, Woods AM, Gallo RC (1981) Clonal Analysis of the Response 
of Human Mveloid Leukemic Cell Lines to Colonv-Stimulating Activity. Blood, 
Aug; 58(2): 285-92.
Salvin SB, Neta R (1983) Resistance and Susceptibility to Infection in Inbred Murine 
Strains. I. Variations in the Response to Thvmic Hormones in Mice Infected with 
Candida Albicans. Cellular Immunology, 75(1): 160-72.
Schafer LA, Goldstein Al, Gutterman JU, Hersh EM (1976) In Vitro and In Vivo Studies 
With Thvmosin in Cancer Patients. New York Academy of Sciences, 277(00): 
609-20.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
97
Scheinberg MA, Goldstein AL, Cathcait ES (1976) Thvmosin Restores T Cell Function 
and Reduces the Incidence of Amvloid Disease in Casein-Treated Mice. The 
Journal of Inununology, Jan; 116(1): 156-58.
Scher HI, Shank B, Chapman R, Geller N, Pinsky C, Gralla R, Kelsen D, Bosl G, Golbey 
R, Petroni G, et al (1988) Randomized Trial of Combined Modalitv Therapv with 
and without Thvmosin Fraction V in the Treatment of Small Cell Lung Cancer. 
Cancer Research, Mar 15; 48(6): 1663-70.
Schulof RS, Low TL, Thurman GB, Goldstein AL 11981) Thvmosins and other hormones 
of the thvmus gland. Progress in Clinical and Biological Research; 58:191-215.
Schulof RS, Lloyd MJ, Ueno WM, Green LD, Stallings JJ (1984) Phase 11 trial of 
Thvmosin Fraction 5 in Advanced Renal Cancer. Journal of Biological Response 
Modifiers, 3(2): 151-59.
Schulof RS, Simon GL, Sztein MB, Parent! DM, DiGioia RA, Courtless JW, Orenstein 
JM, Kessler CM, Kind PD, Schlesselman S, et al (1986). Phase l/II trial of 
thvmosin fraction 5 and thvmosin alpha one in HTLV-III seropositive subjects. 
Journal of Biological Response Modifiers. Oct; 5(5): 429-43.
Schultz RM, Papamatheakis JD, Stylos WA, Chirigos MA (1976) Augmentation of 
Specific Macrophage-Mediated Cvtotoxicitv: Correlation with Agents which 
Enhance Antitumor Resistance. Cellular Immunology, 25(2): 309-16.
Schurmann HI, Van de Wijngaert FP, Delvoye L, Broekhuizen R, McClure JE, Goldstein 
AL, Kater L (1985) Heterogeneity and Age Dependency of Human Thvmus 
Reticulo-Epithelium in Production of Thvmosin Components. Thymus, 7(1): 13- 
23.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
98
Serrate SA, Schulof RS, Leondaridis L, Goldstein Al, Sztein MB (1987) Modulation of 
Human Natural Killer Cell Cvtotoxic Activity. Lvmphokines Production, and 
Interleukin 2 Receptor Expression bv Thvmic Hormones. Journal of Immunology, 
Oct 1; 139(7): 2238-43.
Serrou B, Rosenfeld C, Caraux J, Thierry C, Cupissol D, Goldstein A (1979) Thvmosin 
modulation of suppressor function in mice and man. Annals of the New York 
Academy of Sciences, 332:95-100.
Skomicki AB, Zatz M, Sztein MB, Goldstein AL, Schulof RS (1988) Effect of Thvmic 
Hormones on Interleukin 2 Synthesis bv Lvmphocvtes from HIV-Positive Pre- 
AIDS Subjects. Immunological Investigations Apr; 17(2): 159-64.
Spangelo, BL (1995) Conunentarv: The Thvmic-Endocrine Connection. Journal of 
Endocrinology, 147: 5-10.
Spangelo BL and Gorospe WC (1997) Thvmic polypeptides and their role as mediators in 
neuroendocrine-immune communication. In Stress, Stress Hormones and the 
Immune System, Buckingham et al, eds., John Wiley & Sons, Ltd.
Spangelo BL, Farrimond DD, Pompilius M, Bowman KL (2000) Interleukin 1(3 and 
Thvmic Peptide Regulation of Pituitary and Glial Cell Cvtokine Expression and 
Cellular Proliferation. Annals of the New York Academy of Sciences, 917 
(Neuroimmunomodulation): 597-607.
Spangelo BL, Farrimond DD, Thapa M, Bulathsinghala CM, Bowman KL, Saieh A, 
Hughes FM Jr, Goldstein AL, Badamchian M (1998) Thvmosin Fraction 5 
Inhibits the Proliferation of the Rat Neuroendocrine MMO Pituitary Adenoma and 
C6 Glioma Cell Lines in Vitro. Endocrinology, 139(4): 2155-2162.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
99
Sztein MB, Serrate SA, Goldstein AL (1986) Modulation of Interleukin 2 Receptor 
Expression on Normal Human Lvmphocvtes bv Thvmic Hormones. Proceedings 
of the National Academy of Sciences, USA Aug; 83(16): 6107-11.
Sztein MB, Serrate SA (1989) Characterization of the Immunoregulatorv Properties of 
Thvmosin Alpha 1 on Interleukin-2 Production and lnterleukin-2 Receptor 
Expression in Normal Human Lvmphocvtes. International Journal of 
Immunopharmacology, 11(7): 789-800.
Sztein MB, Simon GL, Parenti DM, Scheib R, Goldstein AL, Goodman R, DiGioia R, 
Paxton H, Skomicki A, Schulof RS (1987) In Vitro Effects of Thvmosin and 
Lithium on Lvmphooroliferative Responses of Normal Donors and HIV 
Seropositive Male Homosexuals with AIDS-Related Complex. Clinical 
Immunology and Immunopathology Jul, 44(1): 51-62.
Tabata T, Kinoshita Y, Fuji S, Hato F, Toyokawa T, Kimura S, Morii H (1989) 
Protection bv Thvmosin fraction 5 from Streptozotocin-induced Diabetes in Mice. 
Cellular and Molecular Biology, 35(2): 121-7.
Thurman GB, Seals C, Low TL, Goldstein AL; (1984) Restorative Effects of Thvmosin 
Polv- Peptides on Purified Protein Derivative-Dependent Migration Inhibition 
Factor Production bv the Peripheral Blood Lvmphocvtes of Adult 
Thvmectomized Guinea Pigs. Journal of Biological Response Modifiers, 3(2): 
160-73.
Tijerina M, Gorospe WC, Bowman KL, Badamchian M, Goldstein AL, Spangelo BL 
(1997) A Novel Thvmosin Peptide Stimulates Interleukin-6 Release fixim Rat C6 
Glioma Cells in Vitro. Neuroimmunomodulation, May-Jun; (3): 163-70.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
100
Wada S, Kinoshita Y, Ozaki Y, Nishio S, Kimura S, Maekawa M (1987) Reduction in 
responsiveness of thvmocvtes to phvtohemagglutinin during bladder tumor 
induction and restorative effects of thvmosin fraction 5 in rats. Journal of the 
National Cancer Institute, Feb; 78(2): 303-6.
Wara DW, Amman AJ (1976) Thvmic Cells and Humoral Factors as Therapeutic Agents. 
Pediatrics, May; 57(5): 643-46.
Watson RR, Lim TS (1986) Thvmosin Fraction 5: Effects on T Cell Functions in Mice 
Inununosuppressed bv Severe Dietary Protein Deficiencv. International Journal 
of Immunopharmacology, 8(6): 545-52.
Wiemik, PH, et al (1991) eds; Neoplastic Diseases of the Blood. 2nd ed, Churchill 
Livingstone Inc, NY.
Witherspoon RP, Hersman J, Storb R, Ochs H, Goldstein AL, McClure J, Noel D, 
Weiden PL, Thomas ED (1983) Thvmosin Fraction 5 Does Not Accelerate 
Reconstitution of Immunologic Reactivitv after Human Marrow Grafting. British 
Journal of Haematology, Dec; 55(4): 595-608.
Woyciechowska J, Goldstein AL, Driscoll B (1985) Experimental Allergic 
Encephalomvelitis in Guinea Pigs. Influence of Thvmosin Fraction V on the 
Disease. Journal of Neuroimmunology, Jan; 7(4): 215-9.
Zatz MM, Goldstein Al (1985) Mechanism of Action of Thvmosin 1. Thvmosin Fraction 
5 Increases Lvmphokine Production bv Mature Murine T Cells Responding in a 
Mixed Lvmphocvte Reaction. Journal of Immunology, Feb; 134(2): 1032-8.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
101
Zatz MM, Oliver J, Goldstein AL, Novak C, Jacobs RP (1984a) Suppressor Cell 
Responses in Patients with Rheumatoid Arthritis: the Effect of Thvmosin. 
Thymus, 6(4): 205-18.
Zatz MM, Oliver J, Samuels C, Skomicki AB Sztein AB, Goldstein AL (1984) 
Thvmosin Increases Production of T-cell Growth Factor bv Normal Human 
Peripheral Blood Lvmphocvtes. Proceedings of the National Academy of 
Sciences USA May; 81(9): 2882-5.
Zatz MM, Skomicki A, Bailey JM, Oliver JH, Goldstein, Al (1985a). Mechanism of 
Action of Thvmosin II. Effects of Aspirin and Thvmosin on Enhancement of lL-2 
Production. Immunopharmacology, Jun; 9(3): 189-98
Zatz, MM, Oliver J, Sztein MB, Skomiki AB, Goldstein AL (1985b) Comparison of the 
Effects of Thvmosin and other Thvmic Factors on Modulation of lnterleukin-2 
Production. Journal of Biological Response Modifiers, Aug; 4(4): 365-76.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
VITA
Graduate College 
University of Nevada, Las Vegas
Melissa Pompilius
Local Address:
612 Donner Street 
Las Vegas, NV 89107
Education:
Bachelor of Science, Chemistiy, 1998 
Northern Arizona University, Flagstaff AZ
Special Honors and Awards:
First Place, Natural and Physical Sciences Platform Presentation, Graduate 
Research Forum. University of Nevada Las Vegas, Las Vegas, NV, April 2000. 
Graduate Research Training Assistantship, University of Nevada, Las Vegas. 
6/2000-8/2000
Graduate Research Training Assistantship, University of Nevada, Las Vegas. 
6/1999-8/1999
Publications:
Bryan L. Spangelo, Deraid D. Farrimond, Melissa Pompilius, and Kay-Lynn Bowman. 
Interleukin-IB and Thvmic Peptide Regulation of Pituitary and Glial Cell Cvtokine 
Expression and Cellular Proliferation. Annals of the New York Academy of Sciences, 
Vol 917, p 597-607, 2000.
Melissa Pompilius, Deraid D. Farrimond, W. David Jarvis, and Bryan L. Spangelo. Anti- 
Proliferative Actions of Thvmic Hormones on HL-60 Human Promvelocvtic Leukemia 
Cells. Abstracts of The Endocrine Society’s 82"^ ° Armual Meeting, Toronto, Canada, 
June 2000.
Thesis Title: The Effects of Thymic Hormones on the Proliferation of Human 
Myelogenous Leukemia Cells
Thesis Examination Committee:
Chairperson, Dr. Bryan Spangelo, Ph D.
Committee Member, Dr. Ronald Gary, Ph D.
Committee Member, Dr. Lydia McKinstry, Ph.D.
Graduate Faculty Representative, Dr. Steen Madsen, Ph D.
102
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
